<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness - Barnes, H - 2016 | Cochrane Library</title> <meta content="Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness - Barnes, H - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011008.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness - Barnes, H - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011008.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011008.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness" name="citation_title"/> <meta content="Hayley Barnes" name="citation_author"/> <meta content="Alfred Health" name="citation_author_institution"/> <meta content="hayleynbarnes@gmail.com" name="citation_author_email"/> <meta content="Julie McDonald" name="citation_author"/> <meta content="Natasha Smallwood" name="citation_author"/> <meta content="Royal Melbourne Hospital" name="citation_author_institution"/> <meta content="Renée Manser" name="citation_author"/> <meta content="and Department of Respiratory Medicine, Royal Melbourne Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011008.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/03/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011008.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011008.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011008.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Opioid [adverse effects, *therapeutic use]; Dyspnea [*drug therapy]; Exercise Tolerance; Morphine [adverse effects, therapeutic use]; Palliative Care [*methods]; Quality of Life; Randomized Controlled Trials as Topic; Terminal Care [*methods]; Time Factors; Walking" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011008.pub2&amp;doi=10.1002/14651858.CD011008.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011008\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011008\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011008.pub2",title:"Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness",firstPublishedDate:"Mar 31, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011008.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011008.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011008.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011008.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011008.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011008.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011008.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011008.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011008.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011008.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14735 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011008.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/appendices#CD011008-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/table_n/CD011008StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/table_n/CD011008StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#CD011008-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hayley Barnes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#CD011008-cr-0003">Julie McDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#CD011008-cr-0004">Natasha Smallwood</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information#CD011008-cr-0005">Renée Manser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information/en#CD011008-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 March 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011008.pub2">https://doi.org/10.1002/14651858.CD011008.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011008-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011008-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011008-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011008-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011008-abs-0001" lang="en"> <section id="CD011008-sec-0001"> <h3 class="title" id="CD011008-sec-0001">Background</h3> <p>Breathlessness is a common and disabling symptom which affects many people with advanced cardiorespiratory disease and cancer. The most effective treatments are aimed at treating the underlying disease. However, this may not always be possible, and symptomatic treatment is often required in addition to maximal disease‐directed therapy. Opioids are increasingly being used to treat breathlessness, although their mechanism of action is still not completely known. A few good sized, high quality trials have been conducted in this area. </p> </section> <section id="CD011008-sec-0002"> <h3 class="title" id="CD011008-sec-0002">Objectives</h3> <p>To determine the effectiveness of opioid drugs in relieving the symptom of breathlessness in people with advanced disease due to malignancy, respiratory or cardiovascular disease, or receiving palliative care for any other disease. </p> </section> <section id="CD011008-sec-0003"> <h3 class="title" id="CD011008-sec-0003">Search methods</h3> <p>We performed searches on CENTRAL, MEDLINE, EMBASE, CINAHL, and Web of Science up to 19 October 2015. We handsearched review articles, clinical trial registries, and reference lists of retrieved articles. </p> </section> <section id="CD011008-sec-0004"> <h3 class="title" id="CD011008-sec-0004">Selection criteria</h3> <p>We included randomised double‐blind controlled trials that compared the use of any opioid drug against placebo or any other intervention for the relief of breathlessness. The intervention was any opioid, given by any route, in any dose. </p> </section> <section id="CD011008-sec-0005"> <h3 class="title" id="CD011008-sec-0005">Data collection and analysis</h3> <p>We imported studies identified by the search into a reference manager database. We retrieved the full‐text version of relevant studies, and two review authors independently extracted data. The primary outcome measure was breathlessness and secondary outcome measures included exercise tolerance, oxygen saturations, adverse events, and mortality. We analysed all studies together and also performed subgroup analyses, by route of administration, type of opioid administered, and cause of breathlessness. Where appropriate, we performed meta‐analysis. We assessed the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and created three 'Summary of findings' tables. </p> </section> <section id="CD011008-sec-0006"> <h3 class="title" id="CD011008-sec-0006">Main results</h3> <p>We included 26 studies with 526 participants. We assessed the studies as being at high or unclear risk of bias overall. We only included randomised controlled trials (RCTs), although the description of randomisation was incomplete in some included studies. We aimed to include double blind RCTs, but two studies were only single blinded. There was inconsistency in the reporting of outcome measures. We analysed the data using a fixed‐effect model, and for some outcomes heterogeneity was high. There was a risk of imprecise results due to the low numbers of participants in the included studies. For these reasons we downgraded the quality of the evidence from high to either low or very low. </p> <p>For the primary outcome of breathlessness, the standardised mean post‐treatment dyspnoea score was 0.32 points better in the opioid group compared to the placebo group (ranging from a 0.53 point reduction to a 0.10 point reduction) (12 RCTs, 338 participants, low quality evidence). The standardised mean change from baseline dyspnoea score was 0.11 points better in the opioids group compared to the placebo group (ranging from a 0.40 point reduction to a 0.19 increase) (six RCTs, 194 participants, very low quality evidence). A lower score indicates an improvement in breathlessness. </p> <p>The evidence for the six‐minute walk test (6MWT) was conflicting. The total distance in 6MWT was 28 metres (m) better in the opioids group compared to placebo (ranging from 113 m to 58 m) (one RCT, 11 participants, very low quality evidence). However, the change in baseline was 48 m worse in the opioids group (ranging from 36 m to 60 m) (two RCTs, 26 participants, very low quality evidence). </p> <p>The adverse effects reported included drowsiness, nausea and vomiting, and constipation. In those studies, participants were 4.73 times more likely to experience nausea and vomiting compared to placebo, three times more likely to experience constipation, and 2.86 times more likely to experience drowsiness (nine studies, 162 participants, very low quality evidence). </p> <p>Only four studies assessed quality of life, and none demonstrated any significant change. </p> </section> <section id="CD011008-sec-0007"> <h3 class="title" id="CD011008-sec-0007">Authors' conclusions</h3> <p>There is some low quality evidence that shows benefit for the use of oral or parenteral opioids to palliate breathlessness, although the number of included participants was small. We found no evidence to support the use of nebulised opioids. Further research with larger numbers of participants, using standardised protocols and with quality of life measures included, is needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011008-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011008-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011008-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011008-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011008-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011008-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011008-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011008-abs-0003" lang="en"> <h3>Opioids for treating breathlessness at the end of life</h3> <p><b>Background</b> </p> <p>People with lung disease may experience breathlessness. Initial treatments should focus on the underlying causes of breathlessness. However, as the disease progresses, it may be better to focus on treating the symptoms. As well as standard care, opioids (e.g. morphine, given either by mouth, by nebuliser, or injected) may help relieve these symptoms. However, opioids also have side effects, such as drowsiness, constipation, nausea (feeling sick), and vomiting. </p> <p><b>Review question</b> </p> <p>We wanted to know if opioid drugs reduced breathlessness in people with lung disease. We also looked at whether opioids improved their ability to exercise, and what side effects people had. We also wanted to know if opioid drugs improved their quality of life. </p> <p><b>Study characteristics</b> </p> <p>We searched for studies up to 19 October 2015, and we included 26 studies with 526 people. These people had breathlessness from different types of lung disease. Some were given opioid drugs and some were given other drugs or a placebo, and studies compared the reporting of breathlessness to see if there was any difference. Some studies also looked at the amount of time people could exercise to see if there were any differences. Some people came from home, and some came from the hospital setting. </p> <p><b>Key findings</b> </p> <p>There was some low quality evidence that showed a benefit of using oral or injectable opioid drugs for the treatment of the symptoms of breathlessness. There was no evidence for opioids by nebuliser. Some people experienced drowsiness, nausea, and vomiting. More research is needed using more people, and looking at effects on quality of life. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence using one of the following grades: very low, low, moderate, or high. Very low quality evidence means we are uncertain about the results. High quality evidence means we are very certain about the results. For this Cochrane review, we found that the evidence was of low to very low quality. We included randomised controlled trials which were blinded, which means that participants and those people that assessed the results did not know whether the participants had received the opioid drug or a placebo. However, the trials were of small size, and some studies did not give enough information to allow us to assess whether they were of good quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011008-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011008-sec-0087"></div> <h3 class="title" id="CD011008-sec-0088">Implications for practice</h3> <section id="CD011008-sec-0088"> <section id="CD011008-sec-0089"> <h5 class="title">For people with breathlessness in advanced disease or terminal illness</h5> <p> <ul id="CD011008-list-0017"> <li> <p>There is low quality evidence showing benefit for the use of oral opioids for the relief of breathlessness in adults with advanced disease and terminal illness. </p> </li> <li> <p>Based on this evidence, it is possible that opioids lead to a short‐term increase in exercise capacity. </p> </li> <li> <p>There is no evidence to support the use of nebulised opioids for the treatment of breathlessness. </p> </li> </ul> </p> </section> <section id="CD011008-sec-0090"> <h5 class="title">For clinicians</h5> <p> <ul id="CD011008-list-0018"> <li> <p>There is low quality evidence showing benefit for the use of oral opioids for the relief of breathlessness in some adults with advanced disease and terminal illness. </p> </li> <li> <p>Based on this evidence, it is possible that opioids lead to a short‐term increase in exercise capacity. </p> </li> <li> <p>It is difficult to draw firm conclusions about the clinical significance of the pooled estimate of treatment effect in our meta‐analysis as we used standardised mean difference (SMD) values to combine studies due to the lack of standardised outcome measures but the magnitude of the treatment effect appears small. </p> </li> <li> <p>There is no evidence to support the use of nebulised opioids for the treatment of breathlessness. </p> </li> </ul> </p> </section> <section id="CD011008-sec-0091"> <h5 class="title">For policy makers</h5> <p> <ul id="CD011008-list-0019"> <li> <p>There is low quality evidence showing benefit for the use of oral opioids for the relief of breathlessness in adults with advanced disease and terminal illness. </p> </li> <li> <p>Based on this evidence, it is possible that opioids lead to a short‐term increase in exercise capacity. </p> </li> <li> <p>It is difficult to draw firm conclusions about the clinical significance of the pooled estimate of treatment effect in our meta‐analysis as we used the SMD to combine studies due to the lack of standardised outcome measures. However, the magnitude of the treatment effect appears small. </p> </li> <li> <p>There is no evidence to support the use of nebulised opioids for the treatment of breathlessness. </p> </li> </ul> </p> </section> <section id="CD011008-sec-0092"> <h5 class="title">For funders</h5> <p> <ul id="CD011008-list-0020"> <li> <p>There is low quality evidence showing benefit for the use of oral opioids for the relief of breathlessness in adults with advanced disease and terminal illness. </p> </li> <li> <p>Based on this evidence, it is possible that opioids lead to a short‐term increase in exercise capacity. </p> </li> <li> <p>It is difficult to draw firm conclusions about the clinical significance of the pooled estimate of treatment effect in our meta‐analysis as we used the SMD to combine studies due to the lack of standardised outcome measures but the magnitude of the treatment effect appears small. </p> </li> <li> <p>There is no evidence to support the use of nebulised opioids for the treatment of breathlessness. </p> </li> <li> <p>Given the small sample sizes of these studies, larger trials may assist in providing more robust evidence for opioids for breathlessness. </p> </li> </ul> </p> </section> </section> <h3 class="title" id="CD011008-sec-0093">Implications for research</h3> <section id="CD011008-sec-0093"> <p> <ul id="CD011008-list-0021"> <li> <p>Given the small sample sizes of these studies, larger trials including more than 50 participants per treatment arm may assist in providing more robust evidence for opioids for breathlessness. </p> </li> <li> <p>Randomised, parallel group trials of longer duration (i.e. greater than one day; for several weeks) are likely to be more clinically appropriate. </p> </li> <li> <p>Effective dosing schedules should be elucidated to determine maximum effect with minimum side effects. </p> </li> <li> <p>Standardised outcome measures should be used including consistent fixed‐point outcome measures of breathlessness, and quality of life measures. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011008-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011008-sec-0015"></div> <div class="table" id="CD011008-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioids compared with placebo in people with breathlessness in advanced disease or terminal illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with refractory breathlessness </p> <p><b>Setting:</b> inpatient and outpatient setting </p> <p><b>Intervention:</b> opioids </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Opioids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: change from baseline<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean change from baseline ranged from −2 to 0.60 in the control group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean change from baseline was 0.11 points better in the opioids group compared to the placebo group (ranging from a 0.40 point reduction to a 0.19 point increase in breathlessness) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: post‐treatment score<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean post‐treatment score ranged from −43 to 49 in the control group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean post‐treatment score was 0.32 points better in the opioid group compared to the placebo group (ranging from a 0.53 point reduction to a 0.10 point reduction in breathlessness) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exercise tolerance: 6MWT<sup>5</sup> ‐ total distance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The total distance in 6MWT was 368m in the placebo group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The total distance in 6MWT was 28 m better in the opioids group compared to placebo (ranging from 113 m to 58 m) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 participants<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3,4,6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exercise tolerance: 6MWT<sup>5</sup>‐ change from baseline</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline was from ‐21m to 37m in the placebo group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in baseline was 48 m worse in the opioids group (ranging from 36 m to 60 m) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> </p> <p><b>constipation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3 (95% CI 1.63 to 5.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> <p>(9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> </p> <p><b>nausea and vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.73 (95% CI 1.73 to 12.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> <p>(7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> </p> <p><b>drowsiness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.86 (95% CI 1.17 to 7.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> <p>(9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><sup>7</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline score in the control group was 2.94</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The quality of life change from baseline score in the opioid group was 0.86 points lower (ranging from 9.90 points lower to 8.18 points higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The study authors assessed breathlessness at variable time points (one hour to six weeks) during the study according to the VAS, Borg scale, and oxygen cost diagram.<br/> <sup>2</sup>There were limitations in the design and implementation of available studies, which suggested a high risk of bias.<br/> <sup>3</sup>There were small study sizes.<br/> <sup>4</sup>There was significant heterogeneity.<br/> <sup>5</sup>The study authors assessed six minute walk test (6MWT) at variable time points (one hour to six weeks).<br/> <sup>6</sup>There were large CIs.<br/> <sup>7</sup>The study authors measured this outcome using the Chronic Respiratory Disease Questionnaire. Only one study included quality of life data that we were able to be include. </p> <p>Abbreviations: RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011008-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine compared with midazolam in people with breathlessness in advanced disease or terminal illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with refractory breathlessness </p> <p><b>Setting:</b> outpatient setting </p> <p><b>Intervention:</b> morphine </p> <p><b>Comparison:</b> midazolam </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Midazolam</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Morphine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: post‐treatment score<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score in the midazolam group was 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean post‐treatment score was 2 points higher in the opioids group (ranging from 1.07 to 2.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63<br/> (1 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The study authors assessed breathlessness according to the numeric rating scale (NRS) for dyspnoea at 5 days.<br/> <sup>2</sup>Limitations in the design and implementation of available studies suggest a high risk of bias.<br/> <sup>3</sup>There was only one study.<br/> <sup>4</sup>There was evidence of significant heterogeneity. </p> <p>Abbreviations: RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011008-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Codeine compared with promethazine in people with breathlessness in advanced disease or terminal illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults</b> with refractory breathlessness </p> <p><b>Setting:</b> outpatient setting </p> <p><b>Intervention:</b> codeine </p> <p><b>Comparison:</b> promethazine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Promethazine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Codeine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: post‐treatment score<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score in the promethazine group was 6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean post‐treatment score was 0.30 points lower in the codeine group (ranging from 0.83 points lower to 0.23 points higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Breathlessness was assessed according to the oxygen cost diagram at 1 month.<br/> <sup>2</sup>Limitations in the design and implementation of available studies suggesting a high risk of bias.<br/> <sup>3</sup>Only one study.<br/> <sup>4</sup>Significant heterogeneity. </p> <p>Abbreviations: RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011008-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011008-sec-0016"></div> <section id="CD011008-sec-0017"> <h3 class="title" id="CD011008-sec-0017">Description of the condition</h3> <p>Breathlessness may be described as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity" (<a href="./references#CD011008-bbs2-0037" title="American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Amercan Journal of Respiratory and Critical Care Medicine1999;159(1):321‐40. ">ATS 1999</a>). Breathlessness, also termed dyspnoea, shortness of breath, air hunger, awareness of respiratory distress, or laboured breathing, may be variably perceived by different patients, depending on multiple physiological, psychological, social, environmental, and cultural factors (<a href="./references#CD011008-bbs2-0053" title="GuzA . Brain, breathing and breathlessness. Respiration Physiology1997;109(3):197‐204. ">Guz 1997</a>). It is a common symptom at the advanced stages of illness, and may be as disabling to the patient and their families as pain, nausea and vomiting, delirium, and other end of life symptoms (<a href="./references#CD011008-bbs2-0064" title="NeumanA , GunnbjörnsdottirM , TunsäterA , NyströmL , FranklinKA , NorrmanE , et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respiratory Medicine2006;100(10):1843‐9. ">Neuman 2006</a>). </p> <p>Respiratory motor activity is regulated by automatic centres in the brainstem and voluntary signals from the cortex, and controls chest wall expansion, lung inflation, and ventilation. Feedback is provided by chemoreceptors, mechanoreceptors, and sensory receptors. Breathlessness may be explained by a mismatch between afferent sensory information processed at the cortex and respiratory motor command from the cortex and brainstem. Alterations in arterial blood pH (acidity), partial pressure of carbon dioxide (pCO<sub>2</sub>), and partial pressure of oxygen (pO<sub>2</sub>) stimulate central chemoreceptors in the medulla and peripheral chemoreceptors in the carotid and aortic bodies, which transmit impulses to the brainstem respiratory centres, and adjust breathing based on acid base homeostasis (<a href="./references#CD011008-bbs2-0063" title="NattieE . Central chemoreceptors. In: DempseyJA , PackAL editor(s). Regulation of Breathing. 2nd Edition. New York: Marcel Dekker, 1995:473‐510. ">Nattie 1995</a>; <a href="./references#CD011008-bbs2-0051" title="FitzgeraldRS , LahiriS . Reflex response to chemoreceptor stimulation. In: CherniackNS , WiddicombeJG editor(s). Handbook of Physiology, Section 3: The Respiratory System, Vol. 2. Control of Breathing. Bethesda: American Physiological Society, 1986:313‐62. ">Fitzgerald 1986</a>). Mechanoreceptors and stretch receptors located in the lung parenchyma and bronchioles sense changes in the expansion of the lung and become irritated by certain mechanical and chemical stimuli, and affect subsequent levels and patterns of breathing (<a href="./references#CD011008-bbs2-0065" title="NishinoT . Dyspnoea: underlying mechanisms and treatment. British Journal of Anaesthesia2011;106(4):463‐74. ">Nishino 2011</a>). Changes in air flow, smooth muscle tone, and impulses from C fibres located adjacent to the alveoli and pulmonary capillaries respond to changes in pulmonary interstitial and capillary pressures (<a href="./references#CD011008-bbs2-0080" title="WiddicombeJG . Pulmonary and respiratory tract receptors. Journal of Experimental Biology1982;100:42‐57. ">Widdicombe 1982</a>). Sensory receptors in respiratory muscle and the diaphragm involved in spinal and supraspinal reflexes influences central respiratory activity (<a href="./references#CD011008-bbs2-0041" title="BolserDC , LindseyBG , ShannonR . Medullary inspiratory activity: influence of intercostal tendon organs and muscle spindle endings. Journal of Applied Physiology1987;62(3):1046‐56. ">Bolsher 1987</a>; <a href="./references#CD011008-bbs2-0042" title="BolserDC , LindseyBG , ShannonR . Respiratory pattern changes produced by intercostal muscle/rib vibration. Journal of Applied Physiology1988;64(6):2458‐62. ">Bolsher 1988</a>). Each of these mechanisms may contribute to the mismatch of neural activity and consequent mechanical and ventilatory outputs, and create sensations of dyspnoea, air hunger, and increased desire to breathe, which may cause distress. </p> <p>Recent neuroimaging studies also suggest that neural structures that involve pain and dyspnoea may be shared, further contributing to the affected person's discomfort and distress associated with an increased sensation of ventilation (<a href="./references#CD011008-bbs2-0043" title="BrannanS , LiottiM , EganG , ShadeR , MaddenL , RobillardR , et al. Neuroimaging of cerebral activations and deactivations associated with hypercapnia and hunger for air. Proceedings of the National Academy of Sciences of the United States of America2001;98(4):2029‐34. ">Brannan 2001</a>; <a href="./references#CD011008-bbs2-0057" title="LiottiM , BrannanS , EganG , ShadeR , MaddenL , AbplanalpB , et al. Brain responses associated with consciousness of breathlessness (air hunger). Proceedings of the National Academy of Sciences of the United States of America2001;98(4):2035‐40. ">Liotti 2001</a>; <a href="./references#CD011008-bbs2-0070" title="ParsonsLM , EganG , LiottiM , BrannanS , DentonD , ShadeR , et al. Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air. Proceedings of the National Academy of Sciences of the United States of America2001;98(4):2041‐6. ">Parsons 2001</a>; <a href="./references#CD011008-bbs2-0072" title="PeifferC , PolineJB , ThivardL , AubierM , SamsonY . Neural substrates for the perception of acutely induced dyspnea. American Journal of Respiratory and Critical Care Medicine2001;163(4):951‐7. ">Peiffer 2001</a>; <a href="./references#CD011008-bbs2-0050" title="EvansKC , BanzettRB , AdamsL , McKayL , FrackowiakRS , CorfieldDR . BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. Journal of Neurophysiology2002;88(3):1500‐11. ">Evans 2002</a>; <a href="./references#CD011008-bbs2-0079" title="vonLeupoldtA , SommerT , KegatS , BaumannHJ , KloseH , DahmeB , et al. Dyspnoea and pain share emotion‐related brain network. NeuroImage2009;48(1):200‐6. ">von Leupoldt 2009</a>). </p> <p>There are many currently incurable and progressive cardiopulmonary, neuromuscular, and malignant conditions in which dyspnoea is a common symptom in the advanced stages of disease. The dominant mechanism that leads to dyspnoea may vary between conditions and in many conditions more than one mechanism may be responsible. Illnesses such as interstitial lung disease, pulmonary hypertension, and congestive heart failure stimulate pulmonary receptors (irritant, mechanical, and vascular) leading to an increased respiratory drive and increased afferent input to the respiratory centre. Chronic conditions that are severe enough might also lead to gas exchange abnormalities through mechanisms such as ventilation‐perfusion (V/Q) mismatching (e.g. pulmonary vascular disease) or diffusion impairment (e.g. interstitial lung disease) leading to stimulation of chemoreceptors and increased respiratory drive. Conditions that reduce the oxygen‐carrying capacity of the blood (e.g. anaemia) or reduce cardiac output (e.g. cardiac failure) also stimulate chemoreceptors. Respiratory muscle weakness in conditions such as motor neurone disease or myopathy, and decreased compliance of the chest wall in conditions such as severe kyphoscoliosis and pleural effusion, impair ventilatory mechanics which reduces the afferent feedback for a given efferent input (<a href="./references#CD011008-bbs2-0060" title="ManningHL , SchwartzsteinRM . Pathophysiology of dyspnea. The New England Journal of Medicine1995;333(23):1547‐53. ">Manning 1995</a>). There are multiple potential aetiological factors related to breathlessness in chronic obstructive pulmonary disease (COPD). There is an increased resistive load from narrowing of the airways and increased elastic load from hyperinflation resulting in impaired ventilator mechanics. In addition, hypoxia and or hypercapnia may be present, leading to stimulation of chemoreceptors, and finally dynamic airway compression may stimulate receptors within the airway (<a href="./references#CD011008-bbs2-0069" title="ParshallMB , SchwartzsteinRM , AdamsL , BanzettRB , ManningHL , BourbeauJ , et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. American Journal of Respiratory and Critical Care Medicine2012;185(4):435‐52. ">Parshall 2012</a>). </p> <p>Multiple mechanisms for breathlessness have also been described in individuals with advanced cancer (<a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>). Cancers that involve the lungs may obstruct airways leading to ventilation perfusion mismatch, and pleural effusions are common. Many people with lung cancer also have COPD. <a href="./references#CD011008-bbs2-0048" title="DudgeonJ , LertzmanM . Dyspnea in the advanced cancer patient. Journal of Pain and Symptom Management1998;16(4):212‐9. ">Dudgeon 1998</a> showed that people with terminal cancer often have abnormal spirometry (most commonly a mixed obstructive/restrictive pattern or a restrictive pattern). They also found that respiratory muscle weakness may be an important contributor to dyspnoea and that co‐morbidities such as anaemia and cardiac disease are common. </p> <p>Initial approaches should aim to treat the underlying causes of breathlessness. However, as the disease progresses, such treatments may be less appropriate due to decreased effectiveness and discomfort caused to the person, and a more symptom‐based approach may be required. </p> <p>Many pharmacological and non‐pharmacological interventions have been recommended to help alleviate symptoms of breathlessness in advanced disease. Management of symptoms is often multimodal, with varying treatments utilised depending on the person's co‐morbidities, and psychosocial, environmental, and cultural factors. </p> <p>A Cochrane systematic review on non‐pharmacological interventions demonstrated efficacy for neuro‐electrical muscle stimulation, chest wall vibration, walking aids, breathing training, and use of hand‐held fans (<a href="./references#CD011008-bbs2-0039" title="BauseweinC , BoothS , GyselsM , HigginsonIJ . Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2] ">Bausewein 2008</a>). Another Cochrane review demonstrated effectiveness of exertional oxygen therapy in non‐hypoxaemic COPD patients (<a href="./references#CD011008-bbs2-0078" title="UronisH , McCroryDC , SamsaG , CurrowD , AbernethyA . Symptomatic oxygen for non‐hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD006429.pub2] ">Uronis 2011</a>), and suggested a slight, but not statistically significant, improvement in adults with heart failure, cancer (not end‐stage disease), and kyphoscoliosis (<a href="./references#CD011008-bbs2-0045" title="CranstonJM , CrockettA , CurrowD . Oxygen therapy for dyspnoea in adults. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD004769.pub2] ">Cranston 2008</a>). </p> <p>Some guidelines recommend opioids as the first‐line pharmacological treatment for breathlessness (<a href="./references#CD011008-bbs2-0037" title="American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Amercan Journal of Respiratory and Critical Care Medicine1999;159(1):321‐40. ">ATS 1999</a>; <a href="./references#CD011008-bbs2-0058" title="MahlerDA , SeleckyPA , HarrodCG , BendittJO , Carrieri‐KohlmanV , CurtisJR , et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest2010;137(3):674‐91. ">Mahler 2010</a>; <a href="./references#CD011008-bbs2-0069" title="ParshallMB , SchwartzsteinRM , AdamsL , BanzettRB , ManningHL , BourbeauJ , et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. American Journal of Respiratory and Critical Care Medicine2012;185(4):435‐52. ">Parshall 2012</a>; <a href="./references#CD011008-bbs2-0059" title="MahlerDA . Opioids for refractory dyspnoea. Expert Review of Respiratory Medicine2013;7(2):123‐35. ">Mahler 2013</a>; <a href="./references#CD011008-bbs2-0081" title="WisemanR , RowettD , AllcroftP , AbernethyA , CurrowDC . Chronic refractory dyspnoea‐‐evidence based management. Australian Family Physician2013;42(3):137‐40. ">Wiseman 2013</a>). A Cochrane review published in 2001 concluded that there was some evidence to support the use of oral and parenteral opioids to palliate breathlessness, but the number of participants studied was small and they recommended that larger trials were needed using standard protocols and incorporating quality of life measures (<a href="./references#CD011008-bbs2-0083" title="JenningsAL , DaviesAN , HigginsJPT , Anzures‐CabreraJ , BroadleyKE . Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database of Systematic Reviews2001, Issue 3. [DOI: 10.1002/14651858.CD002066] ">Jennings 2001</a>). </p> <p>A Cochrane review (<a href="./references#CD011008-bbs2-0077" title="SimonST , HigginsonIJ , BoothS , HardingR , BauseweinC . Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007354.pub2] ">Simon 2010</a>), found no evidence for a beneficial effect of benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD. However, the overall effect size was small and further research is required. </p> </section> <section id="CD011008-sec-0018"> <h3 class="title" id="CD011008-sec-0018">Description of the intervention</h3> <p>Opioids are chemical substances derived from the opium poppy. In the human body they bind to the μ, κ, and δ receptors located in the cerebral cortex, limbic system, midbrain, brainstem, and outside the central nervous system in the bronchioles, alveolar walls, myocardial cells, peripheral sensory nerve fibres, and primary afferent neurons. </p> </section> <section id="CD011008-sec-0019"> <h3 class="title" id="CD011008-sec-0019">How the intervention might work</h3> <p>Exogenous and endogenous opioids specifically bind to the μ receptors to reduce transmission of pain signals (<a href="./references#CD011008-bbs2-0044" title="ChahlLA . Opioids ‐ mechanisms of action. Australian Prescriber1996;19:63‐5. ">Chahl 1996</a>). Opioids also depress respiratory drive by directly blunting the responsiveness of the brainstem centres, which are affected by hypoxia and hypercapnia. Decreased respiratory output results in a decrease in corollary discharge from the brainstem to perceptual areas in the cerebral cortex and thus reduced the sensation of breathlessness. Corollary discharge describes the hypothesis that a sensory 'copy' of the motor output is sent from the motor cortex to the sensory cortex and imparts a conscious awareness of respiratory effort (<a href="./references#CD011008-bbs2-0040" title="BeachD , SchwartzsteinRM . The genesis of breathlessness ‐ what do we understand?. In: BoothS , DudgeonD editor(s). Dyspnoea in Advanced Disease ‐ A Guide to Clinical Management. 1st Edition. Oxford: Oxford University Press, 2006:1‐18. ">Beach 2006</a>). </p> <p>Opioids may also cause blunting of perceptual sensitivity to sensations of breathlessness. Neuroimaging studies demonstrate that μ opioid receptor agonists can modulate the central processing of breathlessness similar to that of pain relief. Administration of opioids stimulate activity in the anterior cingulate cortex, thalamus, frontal cortex, and brainstem, the same areas which are activated when breathlessness occurs (<a href="./references#CD011008-bbs2-0038" title="BanzettRB , MulnierHE , MurphyK , RosenSD , WiseRJ , AdamsL . Breathlessness in humans activate the insular cortex. NeuroReport2000;11(10):2117‐20. ">Banzett 2000</a>; <a href="./references#CD011008-bbs2-0072" title="PeifferC , PolineJB , ThivardL , AubierM , SamsonY . Neural substrates for the perception of acutely induced dyspnea. American Journal of Respiratory and Critical Care Medicine2001;163(4):951‐7. ">Peiffer 2001</a>; <a href="./references#CD011008-bbs2-0073" title="PetrovicP , KalsoE , PeterssonKM , IngvarM . Placebo and opioid analgesia‐‐ imaging a shared neuronal network. Science2002;295(5560):1737‐40. ">Petrovic 2002</a>; <a href="./references#CD011008-bbs2-0071" title="PattinsonKT , GovernoRJ , MacIntoshBJ , RussellEC , CorfieldDR , TraceyI , et al. Opioids depress cortical centers responsible for the volitional control of respiration. Journal of Neuroscience2009;29(25):8177‐86. ">Pattinson 2009</a>). </p> <p>Peripheral opioid receptors are located in bronchioles and alveolar walls of the respiratory tract (<a href="./references#CD011008-bbs2-0082" title="ZebraskiSE , KochenashSM , RaffaRB . Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sciences2000;66(23):2221‐31. ">Zebraski 2000</a>). Opioid administration may modulate breathlessness by binding to these opioid receptors. It is theorised that opioid administration could modulate breathlessness by binding to these peripheral opioid receptors. However, to date, studies of nebulised opioids have lacked efficacy compared with systemically administered opioids, and there is a lack of efficacy when nebulised opioids are compared with systemically administered opioids (<a href="./references#CD011008-bbs2-0074" title="PolosaR , SimidchievA , WaltersEH . Nebulised morphine for severe interstitial lung disease. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD002872] ">Polosa 2002</a>; <a href="./references#CD011008-bbs2-0059" title="MahlerDA . Opioids for refractory dyspnoea. Expert Review of Respiratory Medicine2013;7(2):123‐35. ">Mahler 2013</a>). </p> <p>Other effects of opioids include drowsiness, euphoria, confusion, peripheral vasodilation, constipation, nausea and vomiting, and cough suppression. </p> <p>The choice of preparation and pharmacokinetics of opioids may vary depending on individual needs. Small doses of short‐acting opioids may be commenced in opioid‐naïve people, and once a stable dose has been achieved, may be switched to long acting preparations. <a href="./references#CD011008-bbs2-0046" title="CurrowDC , McDonaldC , OatenS , KennyB , AllcroftP , FrithP , et al. Once‐daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. Journal of Pain and Symptom Management2011;42(3):388‐99. ">Currow 2011</a> found that 70% of participants derived benefit from 10 mg sustained‐release once‐daily preparations. Transmucosal, transdermal, subcutaneous, or intravenous modes may be more appropriate for people whose swallowing is impaired or who are approaching the final stages of end of life. It is unclear if all opioids and all routes are equal in their ability to relieve breathlessness. Opioids differ significantly in their pharmacodynamic properties, from differences in their absorption, to metabolism and affinity for receptors. </p> </section> <section id="CD011008-sec-0020"> <h3 class="title" id="CD011008-sec-0020">Why it is important to do this review</h3> <p>The use of opioids to treat breathlessness in advanced illness is variably accepted in medical practice, and some health professionals and patients have concerns regarding efficacy and side effects (<a href="./references#CD011008-bbs2-0068" title="OxberryS , JonesL , ClarkAL , JohnsonMJ . Attitudes to morphine in chronic heart failure patients. Postgraduate Medical Journal2012;88(1043):515‐21. ">Oxberry 2012</a>; <a href="./references#CD011008-bbs2-0076" title="RockerG , YoungJ , DonahueM , FarquarM , SimpsonC . Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. Canadian Medical Association Journal2012;184(9):E497‐504. ">Rocker 2012</a>). Much of the literature around opioids for breathlessness are narrative reviews and opinion pieces, and a systematic review is required to specifically examine the quality of evidence from randomised controlled trials (RCTs), to evaluate efficacy in terms of symptom control and quality of life, and to assess adverse effects. </p> <p>This review will build on a previous Cochrane systematic review (<a href="./references#CD011008-bbs2-0083" title="JenningsAL , DaviesAN , HigginsJPT , Anzures‐CabreraJ , BroadleyKE . Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database of Systematic Reviews2001, Issue 3. [DOI: 10.1002/14651858.CD002066] ">Jennings 2001</a>). In more recent years, additional RCTs have been published (<a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>), mechanisms of action have been further elucidated, and guidelines that examine the risk of bias and assessment of heterogeneity in Cochrane reviews have been updated (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011008-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011008-sec-0021"></div> <p>To determine the effectiveness of opioid drugs in relieving the symptom of breathlessness in patients with advanced disease due to malignancy, respiratory or cardiovascular disease, or receiving palliative care for any other disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011008-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011008-sec-0022"></div> <section id="CD011008-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011008-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included parallel‐group randomised controlled trials (RCTs) compared to either placebo or other treatment, as well as crossover studies in which participants were randomised to order of treatment. We defined 'randomised' as studies that were described by the study author as 'randomised'. There was no language restriction. All identified trials, published and unpublished, were eligible for inclusion. </p> </section> <section id="CD011008-sec-0025"> <h4 class="title">Types of participants</h4> <p>We considered adults with any type of advanced progressive illness with persistent breathlessness despite optimal or appropriate treatment of reversible factors. </p> <p>We also included participants suffering from breathlessness due to any type of illness, who were considered to be at an advanced stage of illness, or palliative stage, as defined by the study authors. </p> </section> <section id="CD011008-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Any opioid drug, given by any route in any dose, for the treatment of breathlessness compared to placebo, or any other pharmacological or non‐pharmacological interventions that were directly compared with the opioid treatment. </p> </section> <section id="CD011008-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD011008-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>Subjective measurement of breathlessness intensity or severity, including but not limited to Borg and the modified Borg scale, verbal categorical scales of breathlessness, and visual analogue scales (VAS) of breathlessness (<a href="./references#CD011008-bbs2-0067" title="O’DonnellDE , L.M , WebbKA . Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998;158(5):1557–65. ">O'Donnell 1998</a>). </p> </section> <section id="CD011008-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011008-list-0001"> <li> <p>Quality of life measure by any scale.</p> </li> <li> <p>Any physiological and functional assessments of breathlessness including but not limited to six‐minute walk tests (6MWT), shuttle tests, and actigraphy. </p> </li> <li> <p>Performance status.</p> </li> <li> <p>Pulse oximetry.</p> </li> <li> <p>Arterial blood gas analysis.</p> </li> <li> <p>Adverse events including constipation, delirium, and others.</p> </li> <li> <p>Mortality.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011008-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011008-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases up to 19 October 2015.</p> <p> <ul id="CD011008-list-0002"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library) Issue 10 of 12, 2015. </p> </li> <li> <p>MEDLINE (OVID) 1946 to October week 2 2015.</p> </li> <li> <p>EMBASE (OVID) 1974 2015 October 16.</p> </li> <li> <p>CINAHL(EBSCO) 1982 to Octpber 2015.</p> </li> <li> <p>Web of Science (ISI) to October 2015.</p> </li> </ul> </p> <p>We have presented the search strategies we used in <a href="./appendices#CD011008-sec-0097">Appendix 1</a>. </p> </section> <section id="CD011008-sec-0032"> <h4 class="title">Searching other resources</h4> <p>For ongoing studies we searched the following up to 19 October 2015.</p> <p> <ul id="CD011008-list-0003"> <li> <p>The <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/mrct/" target="_blank">http://www.controlled‐trials.com/mrct/</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>). </p> </li> <li> <p>The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>We handsearched reference lists of included studies, relevant chapters, and review articles. We used Google to search for conference abstracts. </p> <p>We attempted to contact the trial investigators of two studies to determine the potential for inclusion. However, we did not receive a reply by the time we completed this review. </p> </section> </section> <section id="CD011008-sec-0033"> <h3 class="title" id="CD011008-sec-0033">Data collection and analysis</h3> <section id="CD011008-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RM and HB) independently screened all abstracts to determine whether they met the inclusion criteria. We sought the full‐text publications of articles that definitely met or may have met the inclusion criteria. Two review authors (RM and HB) then reviewed these full‐text articles to determine eligibility. We resolved any disagreement with discussion and consensus. We included a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) study flow diagram in the review to document the screening process (<a href="./references#CD011008-bbs2-0056" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine2009;151(4):W65‐94. ">Liberati 2009</a>), as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011008-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RM and HB) independently extracted data from the included studies. Where appropriate, we imported data and pooled them in Cochrane's statistical software, Review Manager (RevMan) (<a href="./references#CD011008-bbs2-0075" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), for further analysis. </p> <p>We used a data collection form for study characteristics and outcome data, which we piloted on one study included in the review. </p> <p>We extracted the following data.</p> <p> <ul id="CD011008-list-0004"> <li> <p>Methods: study design, duration of the study, study setting, and date of study.</p> </li> <li> <p>Participants: number, mean age and age range, gender, inclusion and exclusion criteria.</p> </li> <li> <p>Intervention: intervention, dose, mode of administration, concomitant medications, and exclusions. </p> </li> <li> <p>Outcomes: primary and secondary outcomes as specified, type of scale used, and time points collected. </p> </li> <li> <p>Notes: funding for trial and any conflicts of interest for trial authors.</p> </li> <li> <p>'Risk of bias' summary.</p> </li> </ul> </p> <p>We extracted the mean and standard deviation (SD) values from each study. Where the included studies reported standard error or confidence intervals (CIs) were reported, we converted these to SD values according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011008-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two independent authors (HB and RM) assessed the included studies for risk of bias using the Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We assessed the following: allocation (random sequence generation and allocation concealment); blinding of participants and personnel, blinding of outcome assessors; incomplete outcome data; and other bias. We scored each of these domains separately as either low risk of bias, unclear risk of bias (insufficient information to make a judgement), or high risk of bias as outlined below. </p> <p> <ul id="CD011008-list-0005"> <li> <p>Generation of allocation sequence:</p> <ul id="CD011008-list-0006"> <li> <p>for each included study we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups; </p> </li> <li> <p>we assessed the method used to generate the allocation sequence as either: low risk of bias (any truly random process such as random number table or computer random number generator); or unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies that used a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> </ul> </li> <li> <p>Allocation concealment:</p> <ul id="CD011008-list-0007"> <li> <p>for each included study we described the method used to conceal the allocation sequence in sufficient detail and to determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment; </p> </li> <li> <p>we assessed the methods as either: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); or unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list). </p> </li> </ul> </li> <li> <p>Blinding or masking (checking for possible performance bias):</p> <ul id="CD011008-list-0008"> <li> <p>for each included study we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We judged studies at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes; </p> </li> <li> <p>we assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as either: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); or unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We intended to exclude studies that were at high risk of bias and were not double‐blinded. </p> </li> </ul> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). We assessed the methods used to deal with incomplete data as either: low risk (information from all participants were included in the main results, any dropouts are reported, any systematic differences between the two treatment arms are reported); unclear risk of bias (used 'last observation carried forward' analysis); or high risk of bias (used 'completer' analysis). </p> </li> </ul> <ul id="CD011008-list-0009"> <li> <p>Selective reporting bias (checking for within study reporting bias, checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods as either low risk of bias (whether the study fully reported all prespecified outcomes); unclear risk of bias (it appeared not all pre‐outcomes were fully reported); or high risk of bias (the study highlighted not all prespecified outcomes were reported). </p> </li> </ul> <ul id="CD011008-list-0010"> <li> <p>Size (checking for possible biases confounded by small size). Small studies have been shown to overestimate treatment effects, probably because the conduct of small studies is more likely to be less rigorous, allowing critical criteria to be compromised (<a href="./references#CD011008-bbs2-0055" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD011008-bbs2-0066" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. ">Nüesch 2010</a>; <a href="./references#CD011008-bbs2-0047" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. ">Dechartres 2013</a>). We considered studies to be at low risk of bias if they had 200 participants or more in each treatment arm; at unclear risk of bias if they had 50 to 200 participants per treatment arm; or at high risk of bias if they had fewer than 50 participants per treatment arm. </p> </li> </ul> <ul id="CD011008-list-0011"> <li> <p>Free of other bias (bias due to problems not covered elsewhere in the table):</p> <ul id="CD011008-list-0012"> <li> <p>for each included study we described any important concerns we had about other possible sources of bias (e.g. baseline imbalance, bias of the presentation data, representation of gender, etc.). </p> </li> </ul> </li> </ul> </p> <p>We resolved any disagreement by discussion and consensus.</p> <p>We performed funnel plot analysis and compared fixed‐effect versus random‐effects magnitude of effect to determine if there was any suggestion of bias. </p> </section> <section id="CD011008-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We presented results from continuous variables, such as the breathlessness scales, using a fixed‐effect model and calculated standardised mean differences (SMDs) where scales were combined, such as when pooling VAS and Borg scale, with the corresponding 95% CIs. Where scales were not combined, and to assess effect across subgroups, we used the mean difference (MD). Where studies reported results based on a variable range of doses, we used the higher dose. </p> <p>For dichotomous data, including adverse events, we reported relative risk ratios (RRs) where we could pool the data. Where we were unable to pool these data, we included these results in a descriptive analysis. </p> </section> <section id="CD011008-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>Our unit of analysis was the participant. We did not identify any cluster RCTs. We took measurements from the intervention and control group, and analysed the data as if it was a parallel trial, due to lack of paired data available. We attempted to contact the study authors to obtain paired data. However, due to no response we were unable to obtain original data. Most included studies were crossover trials, and therefore we included the data available in data reports, and acknowledged the limitations of this approach. </p> </section> <section id="CD011008-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Where possible we attempted to contact the principal investigator of the included studies to obtain missing data. </p> </section> <section id="CD011008-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>For pooled analyses, we quantified statistical heterogeneity using the I² statistic, which describes the percentage of the total variation across trials due to heterogeneity rather than sampling error. We considered significant statistical heterogeneity to be present if the I² statistic value was greater than 50%. </p> <p>Where we identified significant heterogeneity, we further assessed this using predetermined subgroups. </p> </section> <section id="CD011008-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to contact the principal investigator of the included study for missing data where reporting bias appeared possible. </p> </section> <section id="CD011008-sec-0042"> <h4 class="title">Data synthesis</h4> <p>A priori, we decided to analyse continuous data according to a fixed‐effect model, due to the concerns around the small‐study effects on the results of the meta‐analysis for all continuous outcomes (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). However, we provided random‐effects model data in the sensitivity analysis to compare the sensitivity of the results to different statistical methods. We calculated SMDs where we combined scales, such as when we pooled the VAS and Borg scale data, with the corresponding 95% CIs. Where scales were not combined, and to assess effect across subgroups, we used the MD. Where studies reported results based on a variable range of doses, we used the higher dose. </p> <p>We used RevMan (<a href="./references#CD011008-bbs2-0075" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) to perform meta‐analyses and presented our primary outcomes in a 'Summary of findings' table, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) using the GRADEPro Guideline Development Tool (GDT) software (<a href="./references#CD011008-bbs2-0052" title="McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015. ">GradePro 2015</a>). </p> <p>We assessed the overall quality of the evidence for each outcome using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system (<a href="./references#CD011008-bbs2-0052" title="McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015. ">GradePro 2015</a>) and presented the main findings of the review in a transparent and simple tabular format in the 'Summary of findings' tables. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes. We chose to present the outcomes stipulated a priori and that which would be clinically meaningful. </p> <p>The GRADE system uses the following criteria for assigning the grade of evidence based on RCTs. </p> <p> <ul id="CD011008-list-0013"> <li> <p>High: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low: any estimate of effect is very uncertain.</p> </li> </ul> </p> <p>We decreased the grade of evidence if the following occurred.</p> <p> <ul id="CD011008-list-0014"> <li> <p>Serious (−1) or very serious (−2) limitation to study quality.</p> </li> <li> <p>Important inconsistency (−1).</p> </li> <li> <p>Some (−1) or major (−2) uncertainty about directness.</p> </li> <li> <p>Imprecise or sparse data (−1).</p> </li> <li> <p>High probability of reporting bias (−1).</p> </li> </ul> </p> </section> <section id="CD011008-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses.</p> <p> <ul id="CD011008-list-0015"> <li> <p>Type of illness (e.g. chronic obstructive pulmonary disease (COPD), heart failure, malignancy, and neuromuscular disorders). </p> </li> <li> <p>Mode of delivery of opioid drug (e.g. oral, subcutaneous, intravenous, nebulised, intra‐nasal, sublingual, buccal, transdermal, and other modes). </p> </li> <li> <p>Dose.</p> </li> <li> <p>Type of opioid (e.g. morphine, dihydrocodeine, fentanyl).</p> </li> </ul> </p> <p>In the protocol we indicated that we would perform meta‐analyses according to the subgroups of dose and 'Risk of bias' assessment. Due to the wide variation and heterogeneity of reported doses we chose to analyse this in a descriptive analysis. We compared the 'Risk of bias' difference in a sensitivity analysis. </p> <p>Post‐hoc we chose to include the type of opioid as a subgroup analysis as we felt this would be an important assessment for clinicians and policy makers. </p> </section> <section id="CD011008-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses by systematically excluding studies from the overall analysis based on the potential sources of heterogeneity outlined above, and if homogeneous subgroups have not already been identified and analysed separately. We also compared data from fixed‐effect and random‐effects models to assess for heterogeneity. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011008-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011008-sec-0045"></div> <section id="CD011008-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD011008-sec-0047"> <h4 class="title">Results of the search</h4> <p>We identified 376 citations by using the search strategy, and selected 50 articles for full‐text review after screening the abstracts of the initial search results. See <a href="#CD011008-fig-0001">Figure 1</a> for further details. </p> <div class="figure" id="CD011008-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011008-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We included 26 studies with 526 participants in the review.</p> </section> <section id="CD011008-sec-0048"> <h4 class="title">Included studies</h4> <p>See the '<a href="./references#CD011008-sec-0122" title="">Characteristics of included studies</a>' table. </p> <section id="CD011008-sec-0049"> <h5 class="title">Study characteristics</h5> <p>Eighteen studies with 276 participants provided data for the primary outcome of breathlessness and were included in the meta‐analysis (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>). Four additional studies examined the primary outcome of breathlessness but we were unable to extrapolate data for meta‐analysis (<a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>). Two additional studies did not report the primary outcome, but reported secondary outcomes (<a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>). Two additional studies compared opioids to an intervention other than placebo; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> compared morphine to midazolam, <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a> compared codeine to promethazine. One study (<a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>) compared morphine with oxycodone and placebo. </p> <p>Twenty‐four included studies were crossover trials. <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a> was a parallel group RCT that compared subcutaneous fentanyl with placebo, and <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> was a parallel RCT that compared morphine to midazolam. </p> <p>Most included studies were performed over a fixed period during one day or on two consecutive days, with a washout period of only on day. Six studies involved more chronic administration of the drug or placebo, continuing for study periods between four days and six weeks, with a washout period of between three days and two weeks (<a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). </p> </section> <section id="CD011008-sec-0050"> <h5 class="title">Participants</h5> <p>All included studies were small, with fewer than 50 participants per treatment arm. The number ranged from six to 25 participants, with an average of 19 participants per study. Fourteen studies recruited ambulatory care participants (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>), two studies recruited inpatients (<a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>), one study had a mix of inpatients and outpatients (<a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>), and nine studies did not specify the participant setting (<a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>). </p> <p>Fourteen studies involved primarily or exclusively participants with chronic obstructive pulmonary disease (COPD) (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>; <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>). Six studies included only participants with malignant disease (<a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>), four studies were comprised primarily of cardiac failure participants (<a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>), and one study was comprised of participants with interstitial lung disease (<a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>). One study involved end stage disease from all causes (<a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). </p> </section> <section id="CD011008-sec-0051"> <h5 class="title">Intervention</h5> <p>Eight studies specifically recruited participants not currently on opioids (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a>), who were thus opioid naive. Twelve studies did not specify whether opioid use was part of the exclusion criteria, or whether it formed part of the co‐interventions (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>; <a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>). Three studies examined participants already on opioids (<a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>). <a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a> used 50% more of the participant's usual dose in a PRN (<i>pro re nata</i>, or as required) manner. <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a> used a sliding scale of 30 mcg to 350 mcg fentanyl for all interventional participants, and included regular opioids in both the interventional and control arm. Three studies (<a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>) used a predefined dose of opioids, regardless of the participant's current opioid use. </p> <p>The included studies used the following opioids: oral dihydrocodeine (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a>), oral diamorphine (<a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>), intravenous diamorphine (<a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>), oral morphine (<a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>), nebulised morphine (<a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>), subcutaneous fentanyl (<a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>), subcutaneous morphine (<a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>), nebulised fentanyl (<a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>), oral oxycodone (<a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>), and hydromorphone (<a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>). </p> <p>The doses of dihydrocodeine ranged from 15 mg three times a day to 60 mg three times a day in 1 mg/1 kg doses. The diamorphine dose ranged from 2.5 to 5 mg four times a day. Sustained release morphine was used in 10 to 20 mg doses. Oxycodone was administered in 2.5 mg doses four times a day. Subcutaneous morphine doses ranged from 2.5 to 10 mg. There was a wide range of nebulised morphine doses used, from 1 mg to 50 mg. </p> <p>Nine studies delivered the opioids by the oral route (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>), two studies used parenteral opioids (<a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>), and ten studies gave the drugs via nebulisation (<a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>). Some studies compared different routes of administration. </p> <p>Eight studies continued regular use of co‐interventions including steroids and bronchodilators (<a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a>). Two studies involved the use of oxygen inhalation (<a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>). In both cases the measures were applied to the use of the drug and placebo arm and we felt this did not bias the study results. </p> </section> <section id="CD011008-sec-0052"> <h5 class="title">Outcomes</h5> <p>Twelve studies performed some form of exercise testing (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>; <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>). They used a variety of different exercise tests, including incremental treadmill tests, incremental cycle ergometer tests, non incremental treadmill or endurance treadmill tests, and six‐minute walk tests (6MWT). </p> <p>There was significant variety in the reporting of breathlessness outcome measure, but all studies used well‐validated scales, including the visual analogue scale (VAS), Borg Scale, and oxygen cost diagram (<a href="./references#CD011008-bbs2-0062" title="McGavinCR , ArtvinliM , NaoeH , McHardyGJR . Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. British Medical Journal1978;2(6132):241–3. ">McGavin 1978</a>; <a href="./references#CD011008-bbs2-0067" title="O’DonnellDE , L.M , WebbKA . Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998;158(5):1557–65. ">O'Donnell 1998</a>). Several studies did not report breathlessness at a fixed point during exercise (<a href="./references#CD011008-bbs2-0028" title="BeaufordW , SaylorTT , StansburyDW , AvalosK , LightRW . Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest1993;104(1):175–8. ">Beauford 1993</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>). Some studies did not report the primary outcome of breathlessness, did not include sufficient data, did not report standard deviations (SDs) or error, or reported data in such a way that the relevant numbers could not be extrapolated (<a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>; <a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0011" title="JankelsonD , HosseiniK , MatherLE , SealeJP , YoungIH . Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(10):2270–4. ">Jankleson 1997</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>). </p> <p>In most cases, the studies asked their participants to assess their own levels of breathlessness, by VAS or Borg scale. Some studies asked participants to guess which substance contained the opioid or placebo drug, and other studies offered participants the opportunity to continue on opioid therapy. One study, <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>, used the Chronic Respiratory Disease Questionnaire (CRQ) dyspnoea scale. </p> </section> </section> <section id="CD011008-sec-0053"> <h4 class="title">Excluded studies</h4> <p>See the '<a href="./references#CD011008-sec-0123" title="">Characteristics of excluded studies</a>' section. </p> <p>We excluded eight studies for the following reasons: participants were not randomised (<a href="./references#CD011008-bbs2-0028" title="BeaufordW , SaylorTT , StansburyDW , AvalosK , LightRW . Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest1993;104(1):175–8. ">Beauford 1993</a>; <a href="./references#CD011008-bbs2-0031" title="PetersonGM , YoungRS , DunnePF , GallowayJG , ParksTE . Pilot study of nebulised morphine for dyspnoea in palliative care patients. Australian Journal of Hospital Pharmacy1996;26(5):545–7. ">Peterson 1996</a>; <a href="./references#CD011008-bbs2-0032" title="ShohratiM , GhaneiM , HarandiAA , ForoghiS , Harandi , AA . Effect of nebulized morphine on dyspnea of mustard gas‐exposed patients: a double‐blind randomized clinical trial study. Pulmonary Medicine2012;2012:610921. ">Shorati 2012</a>; <a href="./references#CD011008-bbs2-0033" title="SmithTJ , CoyneP , FrenchW , RamakrishnanV , CorriganP . Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned. Journal of Palliative Medicine2009;12(9):771‐2. ">Smith 2009</a>), there was no comparison to a placebo or other intervention (<a href="./references#CD011008-bbs2-0027" title="AllardP , LamontagneC , BernardP , TremblayCJ . How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. Journal of Pain and Symptom Management1999;17(4):256–65. ">Allard 1999</a>; <a href="./references#CD011008-bbs2-0029" title="BrueraE , SalaR , SpruytO , PalmerL , ZhangT , WilleyJ . Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. Journal of Pain and Symptom Management2005;29(6):613‐8. ">Bruera 2005</a>; <a href="./references#CD011008-bbs2-0030" title="NaviganteAH , CastroM , CerchiettiL . Morphine plus midazolam versus oxygen therapy on severe dyspnea management in the last week of life in hipoxemic advanced cancer patients [Morfina más midazolan versus oxigenoterapia en el control de la disnea severa durante la última semana de vida en pacientes hipoxémicos con cáncer avanzado]. Medicina Paliativa2003;10(1):14‐9. ">Navigante 2003</a>), or it was a review (<a href="./references#CD011008-bbs2-0034" title="ThomasJ , StamblerN , IsraelRJ . Methylnaltrexone, a peripheral opioid antagonist for opioid‐induced constipation in advanced illness: an analysis of dyspnea in patients with chronic obstructive pulmonary disease (COPD) in two double‐blind randomized trials. 18th International Congress on Palliative Care; Oct 5‐8, 2010; Montreal. Journal of Palliative Care2010;26(3):242. ">Thomas 2010</a>). </p> <section id="CD011008-sec-0054"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing studies (<a href="./references#CD011008-bbs2-0035" title="Cuervo PinnaMA . A randomized cross‐over clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. Palliative Medicine2012;26(4):569‐70. ">Cuervo Pinna 2012</a>; <a href="./references#CD011008-bbs2-0036" title="DaubertE , BolestaS . Effect of lorazepam versus morphine on quality of life in hospice patients with dyspnea and anxiety. Journal of the American Pharmacists Association2014;54(2):e193. ">Daubert 2014</a>). </p> </section> </section> </section> <section id="CD011008-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias in the included studies using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and included the domains of allocation, blinding, incomplete outcome data, and other bias. We judged eight studies to be at an overall low risk of bias. We considered 18 studies to be at an overall unclear risk of bias, that is we had insufficient information to make a judgement, usually due to inadequate descriptions of the methods of randomisation or blinding. </p> <p>Please see <a href="#CD011008-fig-0002">Figure 2</a> and <a href="#CD011008-fig-0003">Figure 3</a> for a summary of the 'Risk of bias' findings. </p> <div class="figure" id="CD011008-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD011008-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD011008-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD011008-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>We assessed the overall quality of the evidence for each outcome using the GRADE system (<a href="./references#CD011008-bbs2-0052" title="McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015. ">GradePro 2015</a>) and presented these results in the 'Summary of findings' tables, which shows the main findings of the review in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes. </p> <section id="CD011008-sec-0056"> <h4 class="title">Allocation</h4> <p>We assessed random sequence generation as adequate (low risk) in eight out of 26 studies (<a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>). Most studies (18 studies) did not describe the methods of sequence generation (unclear risk of bias). </p> <p>We judged allocation concealment as adequate (low risk) in eight out of 26 studies (<a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>), which suggests that information from most of the studies presented an unclear risk of bias. Many studies did not state the method of allocation concealment, though many of the studies reported their design as randomised. </p> <p>We did not judge any studies as at high risk of allocation or random sequence generation bias. </p> </section> <section id="CD011008-sec-0057"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel with respect to the intervention was adequate, though blinding of the outcome assessment was overall poor. </p> <p>We judged the blinding of participants and personnel to be adequate in 10 out of 26 studies, indicating low risk of bias (<a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>;<a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>). These studies used placebo interventions, which were reported to have been designed to appear the same as the opioid intervention. We judged blinding of participants and personnel to be at high risk of bias in <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> because only the participants were blinded, not the investigators or those that performed the outcome assessment. Of the 15 studies that we assessed as being at an unclear risk of bias for this domain, the studies did not specifically or adequately describe the details to which the intervention and control were blinded, though many studies reported themselves as blinded. </p> <p>Overall, blinding of the outcome assessment was poor. We assessed only four out of 26 studies as at low risk of bias (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>). We judged <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> to be at high risk as those performing the outcome assessment were not blinded, and we judged the remaining 21 studies to be at an unclear risk of bias. Most studies did not clearly describe the methods by which the outcome assessment was blinded, though some described themselves as double blinded. This may be in part due to the primary outcome of breathlessness requiring the participant to score their own symptoms. </p> </section> <section id="CD011008-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>The included studies generally reported data completely, with 21 out of 26 studies adequately described. We therefore judged them to be at low risk of bias. We judged the remaining five studies to be at an unclear risk of bias (<a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>; <a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>). The included studies usually recorded adverse events, but generally these did not cause participants to drop out of the study. Most studies were conducted on consecutive days, so loss to follow‐up was less likely to occur. </p> </section> <section id="CD011008-sec-0059"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of selective reporting to be low in all studies. We did not detect any evidence of selective reporting bias. </p> </section> <section id="CD011008-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 20 studies to be at low risk for this domain (<a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>; <a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a>; <a href="./references#CD011008-bbs2-0026" title="YoungIH , DaviskasE , KeenaVA . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44(5):387–90. ">Young 1989</a>; <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a>; <a href="./references#CD011008-bbs2-0015" title="LeungR , HillP , BurdonJ . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996;51(6):596–600. ">Leung 1996</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a>; <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>; <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>; <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0024" title="WilliamsSG , WrightDJ , MarshallP , ReeseA , TzengBH , CoatsAJS , et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart2003;89(9):1085‐6. ">Williams 2003</a>; <a href="./references#CD011008-bbs2-0008" title="GrimbertD , LubinO , deMonteM , Vecellio NoneL , PerrierM , CarréP , et al. Dyspnea and morphine aerosols in the palliative care of lung cancer [Dyspnée et aérosols de morphine dans les soins palliatifs du cancer broncho‐pulmonaire]. Revue des Maladies Respiratoires2004;21(6 Pt 1):1091‐7. ">Grimbert 2004</a>; <a href="./references#CD011008-bbs2-0004" title="CharlesMA , ReymondL , IsraelF . Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. Journal of Pain and Symptom Management2008;36(1):29‐38. ">Charles 2008</a>; <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>; <a href="./references#CD011008-bbs2-0012" title="JensenD , AlsuhailA , ViolaR , DudgeonDJ , WebbKA , O’DonnellDE . Inhaled fentanyl citrate improves exercise endurance during high‐intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. Journal of Pain and Symptom Management2012;43(4):706‐19. ">Jensen 2012</a>; <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>), and one at high risk of bias because it did not state that it systematically studied adverse events (<a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>). We judged the remaining five studies to be at unclear risk of other bias because insufficient information was available. </p> <section id="CD011008-sec-0061"> <h5 class="title">Size</h5> <p>The studies were of small sample size, with a mean of 19 participants per study, and with fewer than 50 participants per treatment arm. Thus we judged all 26 studies to be at overall high risk of bias for this domain. </p> </section> </section> </section> <section id="CD011008-sec-0062"> <h3 class="title" id="CD011008-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD011008-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD011008-tbl-0002"><b>Summary of findings 2</b> </a>; <a href="./full#CD011008-tbl-0003"><b>Summary of findings 3</b> </a> </p> <section id="CD011008-sec-0063"> <h4 class="title">Primary outcome: breathlessness</h4> <section id="CD011008-sec-0064"> <h5 class="title">Opioids versus placebo</h5> <section id="CD011008-sec-0065"> <h6 class="title">All studies</h6> <p>The primary outcome of breathlessness was reported in 24 out of 26 included studies. We performed meta‐analysis for the main outcome of breathlessness for 18 studies. We analysed change from before and after administration and post‐administration measurement. We used standardised mean differences (SMDs) since the studies measured comparable outcomes on different scales (the SMD can be converted to units in a VAS or Borg score by multiplying the SD for a particular study). Where studies presented standard errors of the mean, we correlated them to SD. We took measurements from the intervention and control group, and analysed the data as if it was a parallel trial, due to lack of paired data available. This may increase the unit of analysis error. </p> <p>Individually, nine studies reported a statistical benefit using opioids for breathlessness, and 10 studies reported no difference comparing opioids with placebo. Three studies found a significant difference in exercise tolerance, and one found no difference. When we excluded nebulised morphine studies, 10 individual studies found a significant effect on breathlessness, compared to three studies that found no benefit. </p> <p>We have presented meta‐analyses using SMDs in the figures below. We have included fixed‐effect meta‐analyses for opioids compared with placebo for breathlessness outcome for the following. </p> <p> <ul id="CD011008-list-0016"> <li> <p>All studies.</p> </li> <li> <p>By type of opioid.</p> </li> <li> <p>By mode of administration.</p> </li> <li> <p>By condition.</p> </li> </ul> </p> <p>Please see <a href="#CD011008-fig-0004">Figure 4</a> for more details. </p> <div class="figure" id="CD011008-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD011008-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The meta‐analysis demonstrates a small treatment effect for breathlessness (change from baseline, six studies, 194 participants; SMD −0.11, 95% confidence interval (CI) −0.40 to 0.19; P = 0.47 (<a href="./references#CD011008-fig-0008" title="">Analysis 1.1</a>); post‐treatment score, 12 studies, 338 participants, SMD −0.32, 95% CI −0.53 to −0.10; P = 0.004 (<a href="./references#CD011008-fig-0008" title="">Analysis 1.1</a>)). There was statistically significant heterogeneity between the results of the trials for breathlessness change from baseline (I² statistic = 76%, P = 0.0009), but the direction of effect was consistent, and the sample size of the studies was small. We considered the evidence to be of low quality for post‐treatment scores and of very low quality for change from baseline breathlessness. </p> <p><a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a> presented data using the interquartile range and thus we could not pool these data in the meta‐analysis. The study demonstrated a statistically significant improvement in breathlessness from baseline using oral morphine compared to placebo. <a href="./references#CD011008-bbs2-0017" title="MasoodAR , ReedJW , ThomasSH . Lack of effect of inhaled morphine on exercise‐induced breathlessness in chronic obstructive pulmonary disease. Thorax1995;50(6):629–34. ">Masood 1995</a> presented data using CIs with a very small sample size (12 subjects), so we could not pool its data in the meta‐analysis. The study did not demonstrate any statistically significant difference in terms of breathlessness comparing nebulised or intravenous morphine with placebo. <a href="./references#CD011008-bbs2-0006" title="DavisC , PennK , A’HernR , DanielsJ , SlevinM . Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliative Medicine1996;10:64–5. ">Davis 1996</a> reported a post‐treatment score expressed as a percentage of pre‐treatment score change from baseline. The ratio for opioids was 0.64 compared to normal saline of 0.84 was statistically significant at P = 0.001, however the difference in ratios between the two groups was not significant (P = 0.17). </p> </section> <section id="CD011008-sec-0066"> <h6 class="title">Additional sensitivity analyses</h6> <p>We planned <i>a priori</i> to compare data from fixed‐effects and random‐effects models to assess for heterogeneity. There was no difference in effect size or heterogeneity when comparing fixed‐ and random‐effects (<a href="#CD011008-tbl-0004">Table 1</a>). We systematically excluded studies with multiple domains of high risk of bias, and unclear risk of bias (see <a href="#CD011008-fig-0003">Figure 3</a>). When studies with unclear risk of bias were excluded, there was a reduction in effect size and loss of significance. </p> <div class="table" id="CD011008-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis: breathlessness: impact of fixed versus random effects model and unclear bias</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Meta‐analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled SMD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Confidence interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value for SMD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity test</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, fixed‐effect</p> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.40 to 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 76%, P = 0.0009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, random‐effects</p> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.04 to 0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 76%, P = 0.0009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, fixed‐effect</p> <p>Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.53 to −0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 0%, P = 0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, random‐effects</p> <p>Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.53 to −0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 0%, P = 0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies excluded with unclear bias</p> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.29 to 0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 80%, P = 0.0006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies excluded with unclear bias</p> <p>Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.50 to 0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 0%, P = 0.76</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: SMD: standardised mean difference.</p> </div> </div> <p>We have also included an additional <i>post hoc</i> sensitivity analysis to address some of the methodological challenges relating to the quantitative synthesis of the results of cross‐over trials. Cross‐over trials can be an appropriate way to assess short term interventions. The <i>Cochrane Handbook</i> outlines several methods to incorporate crossover data into meta‐analyses (<a href="./references#CD011008-bbs2-0054" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). It states that using the data as if it was a parallel study is a legitimate method, so long as the limitations are acknowledged. In particular this approach can give rise to a unit of analysis error whereby confidence intervals may be wide and the overall effect is under‐estimated. </p> <p>An alternative method is to calculate correlation co‐efficients (which describe the ratio of within patient variation to between patient variation) to impute a corrected standard error. Some included studies provide appropriate data to calculate this (standard error of the differences), or a corrected standard error can be imputed using “borrowed” correlation co‐efficients from other studies. </p> <p>In a subsequent sensitivity analysis we included an alternative meta‐analysis using correlation co‐efficients and corrected standard errors. The data is presented using standardised mean differences. The sensitivity analysis presented, accounting for appropriate use of crossover data, demonstrates a SMD −0.42 (95% CI −0.58 to −0.26); see <a href="#CD011008-fig-0005">Figure 5</a>). This is not dissimilar to our previous SMD −0.32 (95% CI −0.53 to −0.10) for post treatment dyspnoea scores and SMD −0.11 (−0.40 to −0.19) for change from baselines scores; there is a significant but small effect size for the use of opioids for breathlessness. </p> <div class="figure" id="CD011008-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 13 Opioids versus placebo ‐ sensitivity analysis, outcome: 13.1 Breathlessness." data-id="CD011008-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 13 Opioids versus placebo ‐ sensitivity analysis, outcome: 13.1 Breathlessness. </p> </div> </div> </div> <p>In order to interpret this in a more meaningful context, we converted this standard mean difference to a mean difference on a commonly used dyspnoea scale, that being the VAS 100 mm scale. Using the post treatment standard deviation from a large study (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>), we calculated an effect size of 9.6 mm (95% CI −13.44 to −5.52) on a 100 mm VAS scale. The point estimate appears to meet the clinically important difference threshold but the confidence intervals still include values which would not be considered clinically significant and therefore there is still some uncertainty about the effectiveness of the intervention. </p> </section> <section id="CD011008-sec-0067"> <h6 class="title">Type of opioid</h6> <p>There was a strong treatment effect for morphine (post‐treatment scores: six studies, 188 participants; SMD −0.33, 95% CI −0.62 to −0.04; P = 0.02 (<a href="./references#CD011008-fig-0009" title="">Analysis 2.1</a>); change from baseline: four studies, 134 participants, SMD −0.12, 95% CI −0.48 to 0.24; P = 0.50 (<a href="./references#CD011008-fig-0009" title="">Analysis 2.1</a>)), and for dihydrocodeine (post‐treatment score: four studies, 107 participants; SMD −0.41, 95% CI −0.80 to −0.03; P = 0.04 (<a href="./references#CD011008-fig-0010" title="">Analysis 3.1</a>)). </p> <p>There was no effect for hydromorphone (change from baseline: one study, 20 participants, MD −0.26; 95% CI −1.17 to 0.65; P = 0.57), oral diamorphine (post treatment: one study, 10 participants; MD 0.50, 95% CI −1.44 to 2.44; P = 0.61), oxycodone (change from baseline: one study, 35 participants; MD 0.08, 95% CI −0.87 to 1.03; P = 0.16 (<a href="./references#CD011008-fig-0010" title="">Analysis 3.1</a>)), or fentanyl (change from baseline: one study, 10 participants, MD 0.20, 95% CI −2.50 to 2.90; P = 0.88 (<a href="./references#CD011008-fig-0011" title="">Analysis 4.1</a>); post‐treatment score: one study, 12 participants; MD −0.40, 95% CI −2.76 to 1.96; P = 0.74 (<a href="./references#CD011008-fig-0011" title="">Analysis 4.1</a>)). </p> </section> <section id="CD011008-sec-0068"> <h6 class="title">Condition</h6> <p>There were insufficient data to suggest opioids would be more beneficial in any specific condition. The effect for COPD was as follows: change from baseline: two studies, 23 participants, SMD −0.49, 95% CI −1.08 to 0.10; P = 0.1; post‐treatment scores: eight studies, 131 participants; SMD −0.24; 95% CI −0.48 to 0.01; P = 0.1, (<a href="./references#CD011008-fig-0012" title="">Analysis 5.1</a>). For cancer‐related dyspnoea it was: change from baseline: three studies, 39 participants, SMD −0.41; 95% CI −0.89 to 0.06; P = 0.21; post‐treatment score: one study, 10 participants, SMD −0.75; 95% CI −1.67 to 0.16; P = 0.11 (<a href="./references#CD011008-fig-0012" title="">Analysis 5.1</a>). There was no significant difference overall for heart failure (change from baseline: one study, 35 participants; SMD 0.43, 95% CI −0.04 to 0.90, P = 0.08 favouring placebo; post‐treatment score: one study, 12 participants, SMD −0.82, 95% CI −1.66 to 0.02; P = 0.06 favouring opioids), and for interstitial lung disease (one study, six participants; SMD −0.06; 95% CI −1.19 to 1.07; P = 0.92 (<a href="./references#CD011008-fig-0012" title="">Analysis 5.1</a>)). </p> </section> <section id="CD011008-sec-0069"> <h6 class="title">Mode of administration</h6> <p>The effect for oral opioids was as follows: change from baseline: three studies, 58 participants; SMD 0.07, 95% CI −0.30 to 0.44; P = 0.72; post‐treatment score: six studies, 95 participants; SMD −0.27, 95% CI −0.56 to 0.02, P = 0.07 (<a href="./references#CD011008-fig-0013" title="">Analysis 6.1</a>)). For the subcutaneous route it was as follows: change from baseline: two studies, 38 participants; MD −2.30, 95% CI −4.87 to 0.27; P = 0.08, post‐treatment score: one study, 10 participants; MD −19.00, 95% CI −40.15 to 2.15; P = 0.08 (<a href="./references#CD011008-fig-0014" title="">Analysis 6.2</a>)). </p> <p>There was no difference in breathlessness for nebulised opioids compared to placebo (change from baseline: one study, 40 participants; SMD −0.17; 95% CI −0.80 to 0.45; P = 0.58; post‐treatment score: five studies, 116 participants; SMD −0.19; 95% CI −0.56 to 0.17; P = 0.30 (<a href="./references#CD011008-fig-0013" title="">Analysis 6.1</a>)). </p> </section> </section> <section id="CD011008-sec-0070"> <h5 class="title">Opioids versus other interventions</h5> <p><a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> included 63 participants and examined morphine versus midazolam. The study found a statistically significant treatment effect that favoured midazolam for the outcome of breathlessness (MD 2.00, 95% CI 1.07 to 2.93; P &lt; 0.0001; <a href="./references#CD011008-fig-0020" title="">Analysis 10.1</a>). </p> <p><a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a> included seven participants and examined codeine versus promethazine. The effect favoured codeine for breathlessness (MD −0.30; 95% CI −0.83 to 0.23; P = 0.27; <a href="./references#CD011008-fig-0021" title="">Analysis 11.1</a>). </p> <section id="CD011008-sec-0071"> <h6 class="title">Dose</h6> <p>We attempted to calculate the morphine dose equivalent that would confer relief from breathlessness, but due to significant heterogeneity between trials there was no clear dose threshold. We calculated oral morphine equivalent doses and these are represented in the '<a href="./references#CD011008-sec-0122" title="">Characteristics of included studies</a>' tables. <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>, <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a>, <a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>, and <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a> administered 20 mg to 30 mg oral morphine equivalent daily, and three out of four studies found a benefit (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>; <a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>). <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>, <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>, and <a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a> administered 13 mg to 15 mg oral morphine equivalent daily, and two out of three studies found a benefit (<a href="./references#CD011008-bbs2-0013" title="JohnsonMA , WoodcockAA , GeddesDM . Dihydrocodeine for breathlessness in “pink puffers”. British Medical Journal (Clinical Research Edition)1983;286(6366):675–7. ">Johnson 1983</a>; <a href="./references#CD011008-bbs2-0018" title="MazzocatoC , BuclinT , RapinCH . The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double‐blind controlled trial. Annals of Oncology1999;10(12):1511‐4. ">Mazzocato 1999</a>). <a href="./references#CD011008-bbs2-0025" title="WoodcockAA , GrossER , GellertA , ShahS , JohnsonM , GeddesDM . Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. The New England Journal of Medicine1981;305(27):1611–6. ">Woodcock 1981</a>, <a href="./references#CD011008-bbs2-0014" title="JohnsonMJ , McDonaghTA , HarknessA , McKaydSE , DargieHJ . Morphine for the relief of breathlessness in patients with chronic heart failure‐‐a pilot study. European Journal of Heart Failure2002;4(6):753–6. ">Johnson 2002</a>, and <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a> administered 5 mg oral morphine equivalent, and all studies found benefit. <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>, <a href="./references#CD011008-bbs2-0010" title="HuiD , XuA , Frisbee‐HumeS , ChisholmG , Bruera , E . Prophylactic subcutaneous fentanyl for exercise‐induced breakthrough dyspnea: a preliminary double‐blind, randomized controlled trial. Supportive Care in Cancer2013;21:S191. HuiD , XuA , Frisbee‐HumeS , ChisholmG , MorgadoM , ReddyS , et al. Effects of prophylactic subcutaneous fentanyl on exercise‐induced breakthrough dyspnea in cancer patients: a preliminary double‐blind, randomized, controlled trial. Journal of Pain and Symptom Management2014;47(2):209‐17. ">Hui 2014</a>, and <a href="./references#CD011008-bbs2-0003" title="BrueraE , MacEachernT , RipamontiC , HansonJ . Subcutaneous morphine for dyspnea in cancer patients. Annals of Internal Medicine1993;119(9):906‐7. ">Bruera 1993</a> had a wide range of doses and so we could not include these studies in the analysis. </p> <p>There were few studies that calculated the bioequivalence of nebulised morphine to subcutaneous route. It may be as low as 5% (<a href="./references#CD011008-bbs2-0061" title="MasoodAR , ThomasSH . Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. British Journal of Clinical Pharmacology1996;41(3):250‐2. ">Masood 1996</a>). Due to a potentially different mode of action, we did not use nebulised opioid doses to calculate bioequivalence. </p> <p>It is difficult to ascertain the appropriate dose for the relief for breathlessness. It is possible that 5 mg oral morphine daily may confer benefit, but further research is required in this area. </p> <p>We performed a sensitivity analysis that compared fixed‐effect versus random‐effects data, and excluded those with an unclear risk of bias. However, it made very little difference to the overall result (<a href="#CD011008-tbl-0004">Table 1</a>). We also excluded those studies with an unclear risk of bias, which reduced the effect size. </p> <p>We performed funnel plot analysis to estimate the risk of bias by comparing the effect of the intervention effect with each study’s size or precision. In the setting of an intervention effect, and symmetry of the funnel plot, a low risk of publication bias was suggested. </p> <p>Please see <a href="#CD011008-fig-0006">Figure 6</a> for more details. </p> <div class="figure" id="CD011008-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1. Opioids versus placebo, outcome: 1.1 Breathlessness." data-id="CD011008-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1. Opioids versus placebo, outcome: 1.1 Breathlessness.</p> </div> </div> </div> </section> </section> </section> <section id="CD011008-sec-0072"> <h4 class="title">Secondary outcomes</h4> <section id="CD011008-sec-0073"> <h5 class="title">Quality of life</h5> <p>Four studies examined the effects on quality of life. <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a> compared morphine to placebo and used the Chronic Respiratory Disease Questionnaire. The study found no difference in the total score. However, there was a statistically significant difference in the mastery domain scores that favoured placebo, and the study authors suggested that participants may feel less in control when using morphine. This was the only study that presented data that we were able to use for meta‐analysis (<a href="./references#CD011008-fig-0016" title="">Analysis 8.1</a>). <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a> compared morphine to placebo and found no statistically significant difference in well being. <a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a> compared oral morphine to placebo and reported that there was no significant difference in overall sense of well being, although these data were not reported. <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a> comparing oral morphine, oral oxycodone, and placebo in heart failure participants and reported no difference in the SF‐12, a well‐validated 12 question survey for quality of life, although we did not present these data. </p> </section> <section id="CD011008-sec-0074"> <h5 class="title">Exercise tolerance</h5> <p>Fourteen studies examined exercise tolerance, including 12 studies that compared opioids versus placebo. </p> <p>Please see <a href="#CD011008-fig-0007">Figure 7</a> for more details. </p> <div class="figure" id="CD011008-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="original image" data-id="CD011008-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Meta‐analysis demonstrated a significant improvement in maximal workload achieved (four studies, 35 participants; MD −1.70; 95% CI −3.29 to −0.10; P = 0.04), and in maximum work cycle (one study, 12 participants; MD −1.30; 95% CI −1.81 to −0.79; P &lt; 0.00001) (<a href="./references#CD011008-fig-0015" title="">Analysis 7.1</a>). </p> <p>There was an improvement of change in treadmill distance of 37.64 m that favoured opioids (two studies, 30 participants; MD −37.64, 95% CI −96.17 to 20.88; P = 0.21), and an improvement in time on treadmill of 13.42 seconds that favoured opioids (three studies, 38 participants; MD −13.42, 95% CI −42.55 to 15.70; P = 0.37). </p> <p>There were conflicting results for the effect of opioids on the effects of the 6MWT. The change from baseline distance demonstrated a benefit that favoured placebo (two studies, 26 participants; MD 47.78, 95% CI 35.88 to 59.67; P &lt; 0.00001, with significant heterogeneity, I² statistic = 88%, P = 0.003), which was largely due to one study (<a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a>). The effect for the 6MWT total distance was as follows; one study, 11 participants; MD −28.00, 95% CI −113.58 to 57.58; P = 0.52) (<a href="./references#CD011008-fig-0015" title="">Analysis 7.1</a>). </p> <p><a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a> assessed minute ventilation in morphine compared with promethazine, and found no difference in workload or minute ventilation. </p> <p><a href="./references#CD011008-bbs2-0023" title="RiceKL , KronenbergRS , HedemarkLL , NiewoehnerDE . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. British Journal of Diseases of the Chest1987;81(3):287–92. ">Rice 1987</a> assessed a 12‐minute walk test in codeine compared to promethazine, and found no statistical significance. </p> <p>There were no long‐term data presented for exercise tolerance.</p> <p>We graded the evidence as of low methodological quality due to the small size of the included trials, significant heterogeneity across trials, and inconsistency of outcome measurements. </p> </section> <section id="CD011008-sec-0075"> <h5 class="title">Performance status</h5> <p>No studies examined performance status.</p> </section> <section id="CD011008-sec-0076"> <h5 class="title">Pulse oximetry</h5> <p>Twelve studies measured pulse oximetry, but all found no difference between opioid and placebo treatment. </p> </section> <section id="CD011008-sec-0077"> <h5 class="title">Arterial blood gas analysis and end tidal carbon dioxide measurement</h5> <p>Only three studies performed arterial blood gas analysis (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0007" title='EiserN , DenmanWT , West , C Luce P . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. European Respiratory Journal1991;4(8):926‐31. '>Eiser 1991</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>). All found no significant difference in arterial oxygen or carbon dioxide levels. Four studies performed end tidal carbon dioxide analysis (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>; <a href="./references#CD011008-bbs2-0009" title="Harris‐EzeAO , SridharG , ClemensRE , ZintelTA , GallagherCG , MarciniukDD . Low‐dose nebulized morphine does not improve exercise in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine1995;152(6):1940‐5. ">Harris‐Eze 1995</a>; <a href="./references#CD011008-bbs2-0016" title="LightRW , StansburyDW , WebsterJS . Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996;109(4):975–81. ">Light 1996</a>; <a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>). Three studies found no significant difference, and one study found a statistically significant increase in end tidal carbon dioxide levels in the dihydrocodeine group compared to placebo (<a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>). </p> </section> <section id="CD011008-sec-0078"> <h5 class="title">Adverse events</h5> <p>Adverse events from opioids are well recognised, and may be part of the practitioner's reluctance to prescribe in the setting of breathlessness. Only 14 studies reported any adverse events, and only nine studies reported data that we were able to use in meta‐analyses (<a href="./references#CD011008-fig-0017" title="">Analysis 9.1</a>; <a href="./references#CD011008-fig-0018" title="">Analysis 9.2</a>; <a href="./references#CD011008-fig-0019" title="">Analysis 9.3</a>). The adverse effects reported included drowsiness, nausea and vomiting, and constipation. In those studies, participants who were 4.73 times more likely to experience nausea and vomiting compared to placebo, three times more likely to experience constipation, and 2.86 times more likely to experience drowsiness. Twelve participants across all studies stopped the trial early due to adverse events in the treatment arm (one participant due to drowsiness and five due to nausea and vomiting (<a href="./references#CD011008-bbs2-0002" title="Bar‐OrD , MarxJA , GoodJ . Breathlessness, alcohol and opiates. The New England Journal of Medicine1982;306(22):1363–4. ">Bar‐Or 1982</a>); three participant s withdrew due to morphine related side effects (<a href="./references#CD011008-bbs2-0001" title="AbernethyAP , CurrowDC , FrithP , FazekasBS , McHughA , BuiC . Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003;327(7414):523‐8. CurrowDC , PlummerJ , FrithP , AbernethyAP . Can we predict which patients with refractory dyspnea will respond to opioids?. Journal of Palliative Medicine2007;10(5):1031‐6. ">Abernethy 2003</a>); two participants withdrew from <a href="./references#CD011008-bbs2-0021" title="OxberrySG , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Minimally clinically important difference in chronic breathlessness: every little helps. American Heart Journal2012;164(2):229‐35. OxberrySG , TorgersonDJ , BlandJM , ClarkAL , ClelandJG , JohnsonMJ . Short‐term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure2011;13(9):1006–12. ">Oxberry 2011</a> due to bowel and bladder symptoms; and one participant withdrew from <a href="./references#CD011008-bbs2-0022" title="PoolePJ , VealeAG , BlackPN . The effect of sustained‐release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(6):1877–80. ">Poole 1998</a> due to severe constipation). </p> </section> <section id="CD011008-sec-0079"> <h5 class="title">Mortality</h5> <p>Three participants died during the <a href="./references#CD011008-bbs2-0020" title="NosedaA , CarpiauxJP , MarksteinC , MeyvaertA , deMaertelaerV . Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. European Respiratory Journal1997;10(5):1079–83. ">Noseda 1997</a> study. However, the study authors did not believe that this was related in any way to the study interventions. All of these participants had advanced disease and the deaths were likely to be expected. </p> </section> </section> <section id="CD011008-sec-0080"> <h4 class="title">Quality of the evidence</h4> <p>We assessed the quality of evidence from the included studies as of low to very low quality. We only included RCTs, although some studies provided an incomplete description of randomisation. We aimed to included double blind RCTs, however two studies were only single blinded. There was inconsistency in the reporting of outcome measures. We analysed the data according to a fixed‐effect model due to small study bias, and for some outcomes heterogeneity was high. There was a risk of imprecise results due to the low numbers of included participants. For these reasons we downgraded the quality of the evidence to low for breathlessness post‐treatment score, and very low for breathlessness change from baseline. </p> <p>Please see the 'Summary of findings' tables for more information (<a href="./full#CD011008-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011008-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011008-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011008-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011008-sec-0081"></div> <section id="CD011008-sec-0082"> <h3 class="title" id="CD011008-sec-0082">Summary of main results</h3> <p>This Cochrane review demonstrates low quality evidence for a small clinically significant effect for oral and subcutaneous opioids compared to placebo in the relief of breathlessness. There is insufficient evidence at this level to suggest that nebulised opioids are more effective than placebo in relieving breathlessness. This may be explained by the difference in pharmacodynamics of opioids. Not all opioids can be administered via inhaled or intranasal modes. In order to be absorbed by the intranasal or intraoral mucosa, opioids need to be lipophilic. Fentanyl fulfils this criterion as it is highly lipid soluble, whereas morphine is hydrophilic. Therefore, morphine is poorly absorbed via this route (<a href="./references#CD011008-bbs2-0039" title="BauseweinC , BoothS , GyselsM , HigginsonIJ . Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2] ">Bausewein 2008</a>). </p> <p>We found that opioids are inferior for the relief of breathlessness when compared to midazolam, based on one study (<a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). This is consistent with the Cochrane Review by <a href="./references#CD011008-bbs2-0077" title="SimonST , HigginsonIJ , BoothS , HardingR , BauseweinC . Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007354.pub2] ">Simon 2010</a>, which demonstrated a non‐significant beneficial effect that favoured benzodiazepines compared to opioids. </p> </section> <section id="CD011008-sec-0083"> <h3 class="title" id="CD011008-sec-0083">Overall completeness and applicability of evidence</h3> <p>The strength of the evidence available is limited by the small sample size of the studies, which involved six to 63 participants with a mean of 19 participants per study, and by the variability of outcome measures utilised, which limits meta‐analysis. </p> <p>Quality and applicability of evidence is also limited in that studies measured the response to intervention shortly after administration, in a crossover study design, often conducted on two consecutive days with the intervention on one day and control the next. Few studies involved multiple doses or titration according to the participants' individual response. </p> <p>We analysed the data as if all the included studies were parallel group trials, due to lack of paired data available. This may introduce a unit‐of‐analysis error, the confidence intervals (CIs) may be too wide, and the data may be under weighted, thus disguising clinically important heterogeneity (<a href="./references#CD011008-bbs2-0049" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). We analysed the data using a fixed‐effect model due to concerns regarding small‐study bias, and this may underestimate clinically important differences. </p> <p>The lack of evidence for nebulised studies may be influenced by the lack of consistency between studies, as nebuliser devices between different studies were not randomised, and particle size and distance from device to mouth varied. Therefore the total amount of opioid reaching the lungs may have varied. </p> <p>The conclusions we can draw from this review are limited to the dosages used in the included studies. The included studies used a wide range of doses, thus an enhanced effect may be seen with higher doses. However, the risk of adverse events, including drowsiness, may also increase. </p> <p>The studies on breathlessness used a variety of different outcome measures, including the Borg and visual analogue scale (VAS). The point at which studies measured the data also varied, and may or may not have included an exercise test. The studies reported data variably as either a change from baseline or post‐treatment change. This variability in data reporting causes difficulty in interpretation, therefore it is recommended that future studies standardise outcome measures. </p> <p>Less than half of the studies included assessed pulse oximetry, and only three studies assessed arterial oxygen and carbon dioxide levels. Only one study found a difference in end tidal carbon dioxide levels (<a href="./references#CD011008-bbs2-0005" title="ChuaT , HarringtonD , PonikowskiP , Webb‐PeploeK , Poole‐WilsonP , CoatsA . Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology1997;29(1):147‐52. ">Chua 1997</a>). It is unlikely that opioids have a significant impact on oxygen levels in the management of breathlessness. </p> <p>Not all studies reported adverse outcomes. The most common symptom was drowsiness, followed by nausea and vomiting, and constipation. Adverse effects caused some participants to withdraw from the trial. These trials used high doses of morphine at 20 mg oral morphine daily or more. Further research is required to determine if the same improvement of breathlessness can be achieved at lower doses with a reduction in adverse events. </p> <p>Very few studies included data on quality of life. This is an important omission as the participants in these studies were all symptomatic, thus quality of life data are particularly relevant. </p> </section> <section id="CD011008-sec-0084"> <h3 class="title" id="CD011008-sec-0084">Quality of the evidence</h3> <p>We assessed the quality of the evidence presented in this Cochrane review using GRADEpro Guideline Development Tool (GDT) software (<a href="./references#CD011008-bbs2-0052" title="McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015. ">GradePro 2015</a>) and presented it in the 'Summary of findings' tables (<a href="./full#CD011008-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011008-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011008-tbl-0003">summary of findings Table 3</a>). We rated the quality of the evidence using the following grades: very low, low, moderate, or high. Very low quality evidence means we are uncertain about the results. High quality evidence means we are very certain about the results. For this review, we found the evidence to be of low quality. </p> <p>We only included randomised controlled trials (RCTs), however 17 out of 26 studies had an unclear risk of bias overall, mostly due to inadequate reporting of randomisation and allocation sequence. We aimed to included double blind RCTs, however two studies were only single blinded. </p> <p>There was significant heterogeneity between studies for the main outcome of breathlessness (I² statistic =74%, P = 0.0009), which may be explained by the small sample size and inconsistency with outcome measures. Therefore, these results should be interpreted with caution. </p> <p>There was a risk of imprecise results due to the low numbers of included participants.</p> <p>For these reasons we downgraded the quality of the evidence to low for breathlessness post‐treatment score, and very low for breathlessness change from baseline. Further research using larger studies for longer duration, with consistent outcome measures, and adequate randomisation and blinding, is likely to have an important impact on our confidence in the estimate of effect and likely to change the estimate. </p> </section> <section id="CD011008-sec-0085"> <h3 class="title" id="CD011008-sec-0085">Potential biases in the review process</h3> <p>We conducted this review in accordance with established Cochrane standards. Two review authors independently screened search results and resolved discrepancies by discussion and consensus. We did not restrict the literature search by language and we translated two studies into English to determine suitability for inclusion. Also we contacted the study authors where it was unclear if a study met the inclusion criteria, though none of the study authors responded. </p> <p>Publication bias is possible, whereby a failure to identify unpublished negative trials could have lead to an overestimation of the effect of opioids for breathlessness. </p> <p>We analysed the data as if all the included studies were parallel group trials, due to lack of paired data available. This may introduce a unit‐of‐analysis error, the CIs may be too wide, and the data may be under‐weighted, thus disguising clinically important heterogeneity (<a href="./references#CD011008-bbs2-0049" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). </p> </section> <section id="CD011008-sec-0086"> <h3 class="title" id="CD011008-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>This review builds on the review by <a href="./references#CD011008-bbs2-0083" title="JenningsAL , DaviesAN , HigginsJPT , Anzures‐CabreraJ , BroadleyKE . Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database of Systematic Reviews2001, Issue 3. [DOI: 10.1002/14651858.CD002066] ">Jennings 2001</a> "Opioids for the palliation of breathlessness in advanced disease and terminal illness", which concluded that there is evidence in favour of use for oral or parenteral opioid drugs to treat breathlessness, and there is no supporting evidence to support the use of nebulised opioids for the treatment of breathlessness. </p> <p>This Cochrane review included a further 11 studies, although we chose not to include all studies previously included by <a href="./references#CD011008-bbs2-0083" title="JenningsAL , DaviesAN , HigginsJPT , Anzures‐CabreraJ , BroadleyKE . Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database of Systematic Reviews2001, Issue 3. [DOI: 10.1002/14651858.CD002066] ">Jennings 2001</a> due to concerns regarding lack of randomisation. </p> <p>We also undertook further subgroup analyses, and found a particular benefit using morphine. </p> <p>This Cochrane review also examined the use of opioids compared to other interventions. Our review included one study, <a href="./references#CD011008-bbs2-0019" title="CerchiettiLCA , Navigante , AH . Midazolam as adjunct therapy to morphine to relieve dyspnea? Authors' reply. Journal of Pain and Symptom Management2007;33(3):234‐6. NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>, which found that opioids were inferior when compared to intravenous midazolam for the relief of breathlessness. This is consistent with the Cochrane review by <a href="./references#CD011008-bbs2-0077" title="SimonST , HigginsonIJ , BoothS , HardingR , BauseweinC . Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007354.pub2] ">Simon 2010</a>, which compared benzodiazepines to any other intervention, and found a small effect that favoured benzodiazepines over opioids in one study, with an overall small effect size. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011008-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011008-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD011008-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD011008-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD011008-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 13 Opioids versus placebo ‐ sensitivity analysis, outcome: 13.1 Breathlessness." data-id="CD011008-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 13 Opioids versus placebo ‐ sensitivity analysis, outcome: 13.1 Breathlessness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1. Opioids versus placebo, outcome: 1.1 Breathlessness." data-id="CD011008-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1. Opioids versus placebo, outcome: 1.1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD011008-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 1 Breathlessness." data-id="CD011008-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Opioids versus placebo, Outcome 1 Breathlessness." data-id="CD011008-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Opioids versus placebo, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Opioids versus placebo, Outcome 1 Breathlessness." data-id="CD011008-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Opioids versus placebo, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Opioids versus placebo, Outcome 1 Breathlessness." data-id="CD011008-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Opioids versus placebo, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Opioids versus placebo, Outcome 1 Breathlessness." data-id="CD011008-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Opioids versus placebo, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Opioids versus placebo, Outcome 1 Breathlessness." data-id="CD011008-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Opioids versus placebo, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Opioids versus placebo, Outcome 2 Breathlessness." data-id="CD011008-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Opioids versus placebo, Outcome 2 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-007-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Opioids versus placebo, Outcome 1 Exercise tolerance." data-id="CD011008-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Opioids versus placebo, Outcome 1 Exercise tolerance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Opioids versus placebo, Outcome 1 Quality of life." data-id="CD011008-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Opioids versus placebo, Outcome 1 Quality of life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Opioids versus placebo, Outcome 1 Adverse events: constipation." data-id="CD011008-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Opioids versus placebo, Outcome 1 Adverse events: constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Opioids versus placebo, Outcome 2 Adverse events: nausea and vomiting." data-id="CD011008-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Opioids versus placebo, Outcome 2 Adverse events: nausea and vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Opioids versus placebo, Outcome 3 Adverse events: drowsiness." data-id="CD011008-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Opioids versus placebo, Outcome 3 Adverse events: drowsiness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Morphine versus midazolam, Outcome 1 Breathlessness." data-id="CD011008-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Morphine versus midazolam, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Codeine versus promethazine, Outcome 1 Breathlessness." data-id="CD011008-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Codeine versus promethazine, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Opioids versus placebo ‐ sensitivity analysis, Outcome 1 Breathlessness." data-id="CD011008-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Opioids versus placebo ‐ sensitivity analysis, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011008-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/urn:x-wiley:14651858:media:CD011008:CD011008-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_t/tCD011008-CMP-013-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Opioids versus placebo ‐ sensitivity analysis, Outcome 1 Breathlessness." data-id="CD011008-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Opioids versus placebo ‐ sensitivity analysis, Outcome 1 Breathlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/media/CDSR/CD011008/image_n/nCD011008-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011008-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Opioids compared with placebo in people with breathlessness in advanced disease or terminal illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with refractory breathlessness </p> <p><b>Setting:</b> inpatient and outpatient setting </p> <p><b>Intervention:</b> opioids </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Opioids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: change from baseline<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean change from baseline ranged from −2 to 0.60 in the control group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean change from baseline was 0.11 points better in the opioids group compared to the placebo group (ranging from a 0.40 point reduction to a 0.19 point increase in breathlessness) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: post‐treatment score<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean post‐treatment score ranged from −43 to 49 in the control group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean post‐treatment score was 0.32 points better in the opioid group compared to the placebo group (ranging from a 0.53 point reduction to a 0.10 point reduction in breathlessness) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exercise tolerance: 6MWT<sup>5</sup> ‐ total distance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The total distance in 6MWT was 368m in the placebo group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The total distance in 6MWT was 28 m better in the opioids group compared to placebo (ranging from 113 m to 58 m) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 participants<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3,4,6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exercise tolerance: 6MWT<sup>5</sup>‐ change from baseline</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline was from ‐21m to 37m in the placebo group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in baseline was 48 m worse in the opioids group (ranging from 36 m to 60 m) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> </p> <p><b>constipation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3 (95% CI 1.63 to 5.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> <p>(9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> </p> <p><b>nausea and vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.73 (95% CI 1.73 to 12.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> <p>(7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events:</b> </p> <p><b>drowsiness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.86 (95% CI 1.17 to 7.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> <p>(9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><sup>7</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline score in the control group was 2.94</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The quality of life change from baseline score in the opioid group was 0.86 points lower (ranging from 9.90 points lower to 8.18 points higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The study authors assessed breathlessness at variable time points (one hour to six weeks) during the study according to the VAS, Borg scale, and oxygen cost diagram.<br/> <sup>2</sup>There were limitations in the design and implementation of available studies, which suggested a high risk of bias.<br/> <sup>3</sup>There were small study sizes.<br/> <sup>4</sup>There was significant heterogeneity.<br/> <sup>5</sup>The study authors assessed six minute walk test (6MWT) at variable time points (one hour to six weeks).<br/> <sup>6</sup>There were large CIs.<br/> <sup>7</sup>The study authors measured this outcome using the Chronic Respiratory Disease Questionnaire. Only one study included quality of life data that we were able to be include. </p> <p>Abbreviations: RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011008-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Morphine compared with midazolam in people with breathlessness in advanced disease or terminal illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with refractory breathlessness </p> <p><b>Setting:</b> outpatient setting </p> <p><b>Intervention:</b> morphine </p> <p><b>Comparison:</b> midazolam </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Midazolam</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Morphine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: post‐treatment score<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score in the midazolam group was 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean post‐treatment score was 2 points higher in the opioids group (ranging from 1.07 to 2.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63<br/> (1 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The study authors assessed breathlessness according to the numeric rating scale (NRS) for dyspnoea at 5 days.<br/> <sup>2</sup>Limitations in the design and implementation of available studies suggest a high risk of bias.<br/> <sup>3</sup>There was only one study.<br/> <sup>4</sup>There was evidence of significant heterogeneity. </p> <p>Abbreviations: RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011008-tbl-0003"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Codeine compared with promethazine in people with breathlessness in advanced disease or terminal illness</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults</b> with refractory breathlessness </p> <p><b>Setting:</b> outpatient setting </p> <p><b>Intervention:</b> codeine </p> <p><b>Comparison:</b> promethazine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Promethazine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Codeine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Breathlessness: post‐treatment score<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score in the promethazine group was 6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean post‐treatment score was 0.30 points lower in the codeine group (ranging from 0.83 points lower to 0.23 points higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates an improvement in breathlessness</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Breathlessness was assessed according to the oxygen cost diagram at 1 month.<br/> <sup>2</sup>Limitations in the design and implementation of available studies suggesting a high risk of bias.<br/> <sup>3</sup>Only one study.<br/> <sup>4</sup>Significant heterogeneity. </p> <p>Abbreviations: RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011008-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis: breathlessness: impact of fixed versus random effects model and unclear bias</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Meta‐analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pooled SMD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Confidence interval</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value for SMD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity test</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, fixed‐effect</p> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.40 to 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 76%, P = 0.0009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, random‐effects</p> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.04 to 0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 76%, P = 0.0009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, fixed‐effect</p> <p>Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.53 to −0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 0%, P = 0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies, random‐effects</p> <p>Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.53 to −0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 0%, P = 0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies excluded with unclear bias</p> <p>Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.29 to 0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 80%, P = 0.0006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies excluded with unclear bias</p> <p>Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.50 to 0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I² statistic = 0%, P = 0.76</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: SMD: standardised mean difference.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis: breathlessness: impact of fixed versus random effects model and unclear bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/full#CD011008-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.40, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.53, ‐0.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Morphine: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.48, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Morphine: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.62, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Dihydrocodeine: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.80, ‐0.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hydromorphone: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐1.17, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oral diamorphine: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐1.44, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Oxycodone: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.87, 1.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fentanyl: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐2.50, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fentanyl: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.76, 1.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 COPD: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.08, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 COPD: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.48, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Heart failure: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [‐0.04, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Heart failure: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.66, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Interstitial lung disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐1.19, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Cancer‐related dyspnoea: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.89, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Cancer‐related dyspnoea: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐1.67, 0.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.30, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oral: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.56, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Nebulised: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.80, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Nebulised: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.56, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.54 [‐5.09, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Subcutaneous: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐4.87, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Subcutaneous: post‐treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.0 [‐40.15, 2.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exercise tolerance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 6MWT: total distance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐28.0 [‐113.58, 57.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6MWT: change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>47.78 [35.88, 59.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Workload (watts)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐3.29, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Treadmill distance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐37.64 [‐96.17, 20.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Time on treadmill</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.42 [‐42.55, 15.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Maximum work cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐1.81, ‐0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐9.90, 8.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events: constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.63, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: nausea and vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.73 [1.73, 12.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.17, 7.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Morphine versus midazolam</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [1.07, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Morphine versus midazolam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Codeine versus promethazine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.83, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Codeine versus promethazine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Opioids versus placebo ‐ sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.58, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 VAS scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.65, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BORG scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.69, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Oxygen cost diagram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐1.33, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 NRS scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.95, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 CRQ scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.32, 0.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Opioids versus placebo ‐ sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011008-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Opioids versus placebo ‐ sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.58, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.42, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Post treatment score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.77, ‐0.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Opioids versus placebo ‐ sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011008.pub2/references#CD011008-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011008.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011008-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011008-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011008-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011008-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011008-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011008\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011008\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011008\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011008\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011008\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011008.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011008.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011008.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011008.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011008.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714504081"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011008.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714504084"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011008.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d704b6da69377',t:'MTc0MDcxNDUwNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 